{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "\"\"\"\n",
    "KEEP THIS (part1)\n",
    "\"\"\"\n",
    "\n",
    "class rawText(object):\n",
    "    def __init__(self, name_file):\n",
    "        self.name_file = name_file\n",
    "        self.lines = None\n",
    "        self.idx = 0\n",
    "\n",
    "    def read_file(self):\n",
    "        \"\"\"Read the file content and store inside class instance\"\"\"\n",
    "        with open(self.name_file, 'r') as in_file:\n",
    "            self.lines = [x.rstrip().replace('“','').replace('”',\"\").replace('\"','')\n",
    "                          .replace('[','(').replace(']',')').replace(\"’\",'')\n",
    "                          .replace(\"—\",'-').replace(\"…\",' ').replace(\"£\",'GBP').replace(\"–\",'-') for x in in_file.readlines()]\n",
    "        return self.lines\n",
    "\n",
    "    def __next__(self):\n",
    "        if not self.lines:\n",
    "            self.read_file()\n",
    "        try: \n",
    "            self.idx += 1\n",
    "            return self.lines[self.idx - 1].rstrip().replace('“','').replace('”',\"\").replace('\"','').replace('[','(').replace(']',')').replace(\"’\",'').replace(\"—\",'-').replace(\"…\",' ').replace(\"£\",'GBP').replace(\"–\",'-')\n",
    "        except IndexError:\n",
    "            raise StopIteration\n",
    "\n",
    "    def __iter__(self): \n",
    "        return self\n",
    "\n",
    "    # replaces your display_file\n",
    "    def __str__(self):\n",
    "        return self.name_file + (\" : \" if self.lines else \"\") + (\n",
    "                                 \"    \".join(self.lines or []))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "C:/Users/ianda/Desktop/Dropbox (NSF CORE)/Coding Projects/Python/Webscrape - Sentiment/HCPsentiment2.csv\n",
      "['Both tisagenlecleucel and axicabtagene ciloleucel carry a black box warning for cytokine-release syndrome (CRS) and for neurologic events. To treat CAR T-cell-induced severe or life-threatening CRS, the FDA expanded the approval of tocilizumab (Actemra) and has required that CAR T-cell therapy be performed only in cancer centers that have completed training in Risk Evaluation and Mitigation Strategy to support its safe use. Currently, about 40 cancer centers are certified to offer CAR T-cell therapy to patients.', 'Weve learned how to grade (CRS), weve learned how to treat it, Dr. Grupp said during an FDA advisory committee meeting on Novartis CD19-targeted therapy. And IL-6 blockade was really the key.', 'Other so-called neurotoxicities-such as confusion or seizure-like activity-have been seen in most CAR T-cell therapy trials. But in nearly all patients the problem is short lived and reversible, Dr. Brentjens said.', 'There was speculation early on that these neurotoxicities might be related to CRS. But although researchers are still trying to get their hands around the mechanisms, he added, I think most investigators (in the field) would agree that theyre distinct from CRS.', 'Furthermore, toxicity is a significant concern with CAR T-cell therapies; severe neurotoxicity has been observed, though the mortality rate for these adverse events remains low, at around 2% to 3% across the approximately 230 patients studied so far, said Shah. Interestingly, ALL seems to have a higher rate of neurologic toxicity with CAR T than other cancers do, an observation that suggests that there are some disease features that are linked with adverse events (AEs). Adults with ALL appear to have even more neurotoxicity than younger patients.3 I have no explanation for this, Shah said.', 'If fever and hypotension do not resolve with tocilizumab, my own personal bias is that more tocilizumab wont help, said Shah, who would resort to steroids in this case. Theyre bad, but theyre not that bad. He urged clinicians not to be afraid to put a patient on steroids as long as they are willing to stop the course once CRS symptoms start to improve.', 'Cerebral edema is another challenging AE, and the answer is nobody knows why cerebral edema was observed among 6 patients treated in Junos trial of its proposed CAR T-cell therapy, JCAR015, which resulted in multiple deaths. The mechanisms of this AE remain elusive.', 'We worry not only about the associated chemotherapy side effects-nausea, vomiting, hair loss-because they do get some low-dose chemotherapy prior to getting CAR T cells, but the unique side effects we recognize with CAR T cells include CRS and neurological toxicities. The CRS can be, in some mild cases, characterized by fevers, chills, slightly low blood pressure that responds to intravenous fluids to, in extreme cases, fevers that are very high, and blood pressure that drops low enough to require medication.', \"In terms of neurological toxicity, some patients don't have any. Others might have mild confusion. In the severe extreme, patients can become comatose or have seizures as a result of neurotoxicity. Thus far, the companies have been very careful in terms of having sites that have experience and adequate training to treat patients. They're limiting the first roll-out to sites that are able to manage these toxicities, because it is a multimodality management.\", 'Questions about toxicity centered on how optimal management should be delivered. Over 60% suggested that patients should be monitored for 1 to 2 weeks after administration. Notably, one-third stated that toxicity might hinder their prescribing of CAR-T therapy.', 'Additionally, the side-effects of immunotherapy can overshadow clinical benefits, and CAR T-cell therapy is proving to be particularly challenging: for example, 95% of patients treated with axicabtagene ciloleucel had adverse events of grade 3 or worse, including haematological and neurological toxicities.', 'When asked about published information from clinical trials, almost half of the participants were not familiar with the efficacy and toxicity data on CAR-T therapy. Despite most respondents labeling CAR-T therapy as a potentially game-changing approach, only 20% had ever referred a patient to a CAR-T clinical trial', 'Our study highlights several findings that are critical to all stakeholders. First and foremost, lack of familiarity with published data might be predictable since studies were conducted in refractory diseases that are commonly treated at academic sites. Overcoming this educational barrier can be achieved through data dissemination, webinars, regional symposia, and other venues.', 'When queried on how their prescribing habits might evolve should CAR-T therapies become FDA approved for indications studied in ongoing and completed clinical trials; only 22% suggested they are unlikely to prescribe CAR-T therapy.', 'Lastly, we inquired about barriers to successful CAR-T implementation; the logistics of administration was the most common barrier, followed by the known and perceived toxicities', 'While the majority believed that medical oncologists should oversee the management of CAR-T-treated patients, 22% believed that engaging critical care physicians will be essential for optimal care', 'We have reported on the very high response rates and durable remission rates in patients with ALL. We have treated more than 300 patients with tisagenlecleucel in clinical trials, and a lot of that information was used for FDA approval of the therapy.', 'Dr. Lonial: In my experience treating patients with multiple myeloma, the benefit from this therapy has been quite striking. In a small clinical study of a second-generation CAR construct targeting the B-cell maturation antigen (BCMA) in multiple myeloma, the overall response rates looked even better than what weve seen with CD19 in lymphoma and ALL.6 Now, these are very, very early days, but I think the responses in durability are going to be quite impressive.', 'Dr. Maloney: We have also published extensively on our clinical trials data in chronic lymphocytic leukemia (CLL), lymphoma, and ALL, and there is clearly a high initial response rate with CAR T-cell therapy. We are seeing remission rates in patients in whom we did not see any type of remission with conventional therapies. Some patients relapse, and we dont know whether patients are cured yet, and there can be serious toxicities with this therapy.', 'Patients undergoing CAR T-cell therapy require leukapheresis, administration of chemotherapy for depletion of lymphocytes and administration of CAR T-cell therapy, and a high proportion of patients receiving CAR T-cell therapy require ICU hospitalizations for cytokine release syndrome, a severe but common side effect of CAR T-cell therapy, Hernandez told HemOnc Today. All of this is related with facility costs - costs reimbursed to the hospital - and physician costs, which, again, are not accounted for by the price tag announced by the manufacturer. setting,10 thereby community oncologists will play an instrumental role in patient referral and likely determine the initial adoption of this treatment.', 'Patients undergoing CAR T-cell therapy require leukapheresis, administration of chemotherapy for depletion of lymphocytes and administration of CAR T-cell therapy, and a high proportion of patients receiving CAR T-cell therapy require ICU hospitalizations for cytokine release syndrome, a severe but common side effect of CAR T-cell therapy, Hernandez told HemOnc Today. All of this is related with facility costs - costs reimbursed to the hospital - and physician costs, which, again, are not accounted for by the price tag announced by the manufacturer.', 'It is important to quantify the total costs of this therapy because these nondrug costs are certainly not negligible. It is important to account for them when doing pharmacoeconomic evaluations of these therapies and deciding on their coverage, Hernandez said. Moreover, the outcomes-based agreements announced for tisagenlecleucel would only refund pharmaceutical costs for nonresponders. So, it would be important, as well, to account for those nondrug costs when payers negotiate pricing agreements with manufacturers.', 'The researchers used the sum of the expected costs in each scenario and the probability of each scenario to determine the mean expected cost per patient.', 'The mean total expected cost of tisagenlecleucel was $510,963. Costs ranged from $478,777 for patients who did not develop cytokine release syndrome to $531,813 for patient who did develop cytokine release syndrome.', 'The mean total expected cost decreased to $432,131 for tisagenlecleucel when researchers adjusted for the outcomes-based pricing arrangement announced by Novartis.', 'Every year about 600 U.S. patients are eligible for tisagenlecleucel. Using the mean total expected cost, the researchers estimated the annual expenditure would be $259 million.', 'The mean total expected cost of axicabtagene ciloleucel was $402,647.', 'With 7,500 U.S. patients eligible for axicabtagene ciloleucel, the estimated annual expenditure would be $3 billion.', 'Nondrug costs accounted for 7% of total costs.', 'However, this doesnt mean that these costs are negligible, because this 7% accounts for $30,000 for the average patient and up to $60,000 for those who present with cytokine release syndrome, Hernandez said.', 'However, although these promising findings are generating much enthusiasm for CAR T-cell therapy-ASCO named adoptive-cell immunotherapy its 2018 Advance of the Year4-it is tempered by their hefty price tags: $475,000 for tisagenlecleucel and $373,000 for axicabtagene ciloleucel. And these prices reflect just the cost of extracting a patients T cells, engineering them to produce CARs on the surface of the cells, and infusing the cells back into the patient. They do not include fees for hospital stays, supportive care, or physician visits, which could drive the total cost to stratospheric levels of more than $1 million per patient, according to some reports.', \"These drugs are very expensive. The ALL product costs about $475,000 and the DLBCL products cost about $375,000, Deol, associate professor with Karmanos Cancer Institute, said. That is just the cost of the cells. This does not include the management of toxicities, and it's not out of the ordinary for the patient's total bill to be close to $500,000 when they're done with treatment. There needs to be a little more research into making this treatment more affordable so that more patients can be treated.\", 'Cost did not appear to be a hindrance to prescribing, as most believed CAR-T would be cost-effective if priced at parity with allogeneic stem cell transplantation.', 'The key driver of the NICE and NHS England decisions has been cost. Axicabtagene ciloleucel is believed to cost more than GBP50?000 per quality-adjusted life-year (QALY) gained, which is at the upper limit of tolerance for cancer treatments. The manufacturer has proposed a commercial arrangement that might sway the eventual decision in favour of approval, although at the time of writing, NICE has requested the manufacturer find more UK data from which a comparison with the current standard of care can be made. Tisagenlecleucel, by contrast, which is presumably costing less than the GBP282?000 list price in the arrangement secured by NHS England, might have a more favourable cost per QALY because children have a longer life expectancy than older patients, provided toxicities are manageable and not debilitating.', 'This past April, the Centers for Medicare and Medicaid (CMS) said it would reimburse hospitals about $400,000 for axicabtagene ciloleucel and $500,000 for tisagenlecleucel. Although outpatients usually have a 20% copayment on Medicare B services, which would mean a copayment of $79,076 for axicabtagene ciloleucel and $100,168 for tisagenlecleucel, the Social Security Act statute requires CMS to cap outpatient copayments at the amount of the inpatient deductible, which is $1,340 in 2018.', 'When tisagenlecleucel was approved in August 2017, Novartis made an outcomes-based agreement with the CMS, which calls for payment to the company for patients who show a morphologic remission within a month after receiving their CAR T-cell infusion. If the patient does not respond within the first month-a majority of patients, about 80%, have an initial response to the therapy-Novartis will not bill those medical facilities that opted in to the outcomes-based agreement.', 'Importantly, most prescribers (46%) plan on referring their patients to large academic centers, while one-third would rather treat some of their patients locally while referring others to academic sites', 'Physicians appear receptive to prescribing CAR-T therapy once regulatory approval is granted, but there was no consensus as to their desire on where treatment should be delivered. While almost half of the respondents suggested that all eligible CAR-T patients should be referred to academic centers, one-third stated that they will refer some but not all of their CAR-T eligible patients. Fewer physicians voiced their willingness to treat these patients locally if allowed by payers and manufacturers. This might be problematic as CAR-T therapy requires highly specialized centers with allogeneic stem cell transplantation capabilities given the uniqueness of observed toxicities.12 While it is unlikely that CAR-T therapy will be given at community sites at launch, this might change in the future.', 'Additional logistical challenges were suggested as major hurdles for CAR-T therapy adoption. Community oncologists voiced their concerns about the operational complexity and the fact that successful CAR-T administration requires harmonized collaboration between the treating facility, manufacturers, and the transportation system. Aligning these stakeholders to assure timely apheresis, collection, transportation, T-cell expansion, and reinfusion might be challenging, especially as eligible patients are often sick, with active disease, and receiving lymphodepleting chemotherapy prior to the infusion.', 'Dr. June: Theoretically, like a lot of biologic therapies, it will be best to use cellular immunotherapies early in the course of a disease, but that will require randomized clinical trials to know for sure. There is a clinical study scheduled to begin this year testing CAR T cells upfront in high-risk patients with pre-B cell ALL, so we should have more information soon.', 'Dr. Lonial: Im not a lymphoma expert, but with all the new therapies, when you are not certain as to where the risks and benefits are going to fall out, it is usually best to treat the sickest patients with the fewest options early on. There are subsets of patients with lymphoma who do quite well with standard chemotherapy, so the real question to me is can we identify the high-risk group of patients before they relapse and expose them to CAR T-cell therapy earlier in the course of disease, after first relapse. For instance, in the context of relapsed large B-cell lymphoma, is a CAR T-cell option better than an autologous transplant? There are clinical studies under way to answer these questions, but well have to wait for the data to know for sure.', 'Dr. Maloney: Cell immunotherapies are not going to be immediately moved to the upfront setting, but the next studies in lymphoma will compare CAR T cells with standard of care for first-relapse disease, which is autologous stem cell transplant. To move CAR T-cell therapy to the actual front-line setting is going to require more work, at least in lymphoma, because the results are good with conventional chemotherapy for most patients. But as soon as conventional chemotherapy does not work in the front-line setting, I can certainly envision a time when CAR T cells would be second-line standard of care. Were not quite there yet, but it will happen.', 'Mr. Touchon: We believe there is a place for this therapy in the earlier treatment setting, but we need to prove it is appropriate in specific clinical studies. We are planning a study this year with tisagenlecleucel in patients with DLBCL after first relapse and also a small trial of tisagenlecleucel in the first-line setting in very high-risk pediatric patients with B-cell ALL.', 'Additional analysis of data from the ELIANA clinical trial shows impressive results in 75 patients treated with tisagenlecleucel. The analysis found the overall remission rate within 3 months was 81%; the rates of event-free survival were 73% at 6 months and 50% at 12 months; overall survival was 90% and 76% over the same time intervals.', 'Follow-up analysis of results from the ZUMA-1 trial investigating the effectiveness of axicabtagene ciloleucel in patients with refractory NHL also shows impressive outcomes. According to the analysis, more than 1 year after treatment, 42% of the 108 patients enrolled in the trial had maintained remission, and 40% of the patients exhibited no evidence of cancer. In addition, more than half of the patients were alive at the median follow-up of 15.4 months-more than double the median survival of 6.6 months for patients treated with conventional therapy.', 'The progress made with CAR T-cell therapy in children with ALL has been fantastic, said Terry Fry, M.D., a lead investigator on several POB trials of CAR T cells. CD19-targeted CAR T cells were initially tested in adults. But the fact that the first approval is for a therapy for children and adolescents with ALL is a watershed moment, Dr. Fry continued.', 'Our data provide the first true glimpse of the potential of this approach in patients with aggressive lymphomas, who, until this point, were virtually untreatable, said the trials lead investigator, James Kochenderfer, M.D., of the NCI Experimental Transplantation and Immunology Branch.', 'The results in lymphoma to date have been incredibly successful, Dr. Kochenderfer said, and CAR T cells are almost certain to become a frequently-used therapy for several types of lymphoma.', 'First, said Shah, Adult ALL doesnt get enough attention, but it does account for nearly half of all the all cases that we see. Adult patients with ALL are more likely to relapse, and their outcomes are typically poor, with an average survival of roughly 40%. I think we have a lot of room for improvement there, said Shah.', 'Allogenic transplant may help these patients, and while inotuzumab does improve overall survival, its not easy to get excited about long-term survival improvements of only small percentages. With blinatumomab, a T-cell directed therapy, We did better than chemotherapy for a short while, Shah explained; however, even with blinatumomab, long-term survival remains around 25%, so were still having trouble getting past this hurdle.', 'In addition to the challenge posed by manufacturing time, data also show that adults had worse outcomes than children when treated with tisagenlecleucel,1 and Thats disconcerting   as we decrease the age we see better responses. This is discouraging for adult patients; We are absolutely improving survival, said Shah, but Why do adults have to take the short end of the stick?', 'The reason these products were approved was based on results of clinical trials. ZUMA-1 (with axi-cel) looked at relapsed/refractory DLBCL and the overall response rate was close to 80%. However, the complete response (CR) rate around 12 to 18 months is approximately 40% to 45%. There are patients who respond, but unfortunately did relapse after treatment. Therefore, there needs to be more research into preventing relapse and keeping these patients in remission.', 'Tisagenlecleucel was also explored in a multicenter study that looked at a few hundred patients who were treated with the product; their response rates were around 55% to 60% with, again, long-term CR rates in the 40% to 45% range. We have seen some differences in terms of the upfront responses, but if you look at the long-term CR data for both studies, they seem to be similar in the 40% to 50% range.', 'The main issue regarding these decisions is whether CAR T-cell therapy is more effective than current standard of care-and therein lies a problem. There are no prospective, head-to-head comparisons with existing care. Currently, CAR T-cell therapy is only considered in experimental settings after exhausting all other treatment options and is thus used as a treatment of last resort, limiting the available evidence. In the UK, only 200 of about 5000 people diagnosed each year with diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma might be eligible for CAR T-cell therapy, and only 15-20 of 400 children each year with acute lymphoblastic leukaemia. The current evidence for axicabtagene ciloleucel is from a phase 2 trial of 101 patients with refractory disease, which showed an objective response of 82%. For tisagenlecleucel, a non-comparative, phase 1-2 trial of 75 patients, reported a remission within 3 months of 81%. Taken alone, these results seem promising, but the lack of control group in both trials and the choice of surrogate primary endpoints make the benefits difficult to discern.', 'But there is still more to do with existing CAR T-cell therapies, Dr. Fry said.', 'He is particularly enthusiastic about the potential to use CAR T cells earlier in the treatment process for children with ALL, specifically those who are at high risk (based on specific clinical factors) of their disease returning after their initial chemotherapy, which typically is given for approximately 2 and a half years.', 'In this scenario, he explained, if early indicators suggested that these high-risk patients werent having an optimal response to chemotherapy, it could be stopped and the patients could be treated with CAR T cells.', 'For patients who respond well, they could be spared 2 more years of chemotherapy, Dr. Fry said. Thats amazing to think about.', 'In looking to the future, Shah says that off-the-shelf CAR T-cell therapies will be key to treating more patients, and that improving on current toxicities will be key. Finally, improving the durability of response will be necessary: Post-CAR T relapse is going to be a big problem, and I dont know how to solve it  We have to worry about the fact that response isnt durable.', 'Investing in resources that facilitate safe and effective CAR-T therapy in nonacademic entities is an essential strategy for payers and manufacturers to ensure that eligible patients receive this therapy. Travel to academic sites is not always feasible and certainly represents a logistical barrier for any specialized therapy or procedure.13 Timely referral and having proper channels between community and academic sites is critical given the seriousness of illnesses that CAR-T are indicated to treat.', '...long-term follow-up data on the safety of these therapies are essential.', 'Mr. Touchon: I agree that cost is an important topic. When we considered the price of tisagenlecleucel in the United States, the first thing we looked at was its medical value and the value it brings to patients, as evidenced by the ELIANA study. Then we looked at the value to the health-care system and society. Many of the patients with ALL treated with tisagenlecleucel were able to resume their normal life, and their parents and caregivers were also able to resume their normal lives, so the therapy has societal value in addition to patient value.', 'The health-care system value was based on the cost-effectiveness studies we conducted. The results from our studies found that pricing the therapy between $600,000 and $750,000 would have been cost-effective to the health-care system, but we decided instead to have a list price of $475,000. Since then, the National Institute for Health and Care Excellence and the Institute for Clinical and Economic Review have confirmed the cost-effectiveness of tisagenlecleucel.', 'It was important for Novartis to find a price for this one-time therapy that allows patients to access care through the U.S. health-care system and that also takes into account the innovation and investment to develop such a transformative therapy. We have implemented and support programs and outcomes-based agreements to further facilitate patient access to this therapy.', 'I think we can all agree that health insurance is already quite expensive in the U.S., and nobody likes to see premiums increase, she added. But if we dont want premiums to keep increasing, it is necessary to evaluate new therapies thoroughly and assess the benefit they bring for their cost, and how that ratio compares to that of other health services.', \"The important thing is to first determine whether the patient meets criteria for the FDA-approved indication, because insurance companies carefully look at that to determine whether they'll cover someone treated with CAR T cells. That has been a challenge.\", 'It is within this context that the excitement surrounding CAR T-cell therapy is balanced against the reality of another case of false hope. Many patients might feel that they are missing out on a new wonder drug, a feeling that might be further exacerbated by international differences in eligibility criteria; for example, the threshold of minimally residual disease at which a child is eligible for CAR T-cell therapy is more liberal in the USA than in the UK. But these differences are misleading and are a consequence of the scant clinical evidence available currently, and the subjective nature of clinical decision making for these specific treatments.', 'Payers should factor in nondrug costs when making decisions on the coverage of these therapies and when negotiating prices with manufacturers. For the health care systems perspective, the key point is that health care resources are not unlimited, Hernandez told HemOnc Today. Money needed to cover new highly expensive therapies with a high budget impact, such as CAR T-cell therapy, needs to come from somewhere - either from a reallocation of funds from other therapies and health services that will no longer be covered or from increased premiums.', 'Programs like Novartiss outcomes-based pricing for tisagenlecleucel may help curb costs; however, the impact on the health care system is large, Hernandez said.', 'Dr. June: To begin, there are CD19 CAR T cells, and the initial response rate and remission durations are very different depending on the type of cancer the patient has. The first patients we treated with CLL in 2010 are still in remission. We have the most durability data in patients with CLL, and its very rare to relapse, but the remission rate is about 50% currently. In ALL, the remission rate in multiple studies is between 80% and 90%. In one of our trials, there was a 28% relapse rate after 1 year, but after that, it is very rare to experience relapse, and the relapses that do occur are usually due to the loss of the CD19 part of the molecule on the leukemia cells. Thats different from what happens in lymphoma, where the complete response rate is 40%, and its rare to have relapses in those patients; when they do relapse, it is not usually with a CD19 target loss like in ALL. What happens after patients are treated depends on what type of tumor they have. There is not a one-size-fits-all treatment.', 'When patients relapse after conventional therapy, they may go on to other experimental therapies, including newer generations of CAR T cells. However, when patients relapse after CAR T-cell therapy, unfortunately, they usually die of their disease.', 'Dr. Lonial: Many trials are now allowing patients to be re-treated, so re-treating may make sense. What weve seen, particularly in lymphoma and ALL, is the idea that these patients were treated with very early-generation CAR T cells; if these were the only data we had, I probably would not be as excited about the potential for this therapy to revolutionize the field.', 'Youre right. Not all patients respond to the therapy, and the durability of responses can be limited; some of that may be due to patients dealing with end-stage disease, when its much more difficult to achieve a long-term response. For me, what shifted the potential applicability of CAR T cells in cancer were the data we saw in myeloma: Even in refractory disease, 90% of patients were having a major response to the therapy. And in the follow-up data weve seen, many of those patients, over two-thirds, are staying in remission close to a year out. These results suggested to me there may be modifications and evolution in the way we think about making CAR T cells and delivering them that may continue to improve outcomes for patients.', 'We are launching a trial at our center combining tisagenlecleucel with programmed cell death protein 1 (PD-1) inhibitors in patients with lymphoma to try to improve the longevity of the cell and ultimately the long-term antitumor effects of the therapy. Its just a matter of figuring out, in a deliberate and scientific way, what are the best treatment combinations and who are the patients being treated; it is not just the CAR T-cell product we have to look at, it is the quality of the T cells being used to make the product as well. What we can do to the host to augment the production of effective T cells and what we can do to the cells once they have been extracted to augment their efficacy and long-term benefit are being investigated now.', 'Dr. Maloney: In my experience, it is seldom effective to re-treat patients with this therapy. Occasionally, the same patients may respond to the same CAR T cells, but in many cases, the reason they relapse and the reason the therapy may be ineffective are the patients immune system rejects the CAR T cells, because they are a foreign protein on the surface of the T cells. Its important to note the three CARs likely to be approved in lymphoma in the near future, including JCAR017, all use the same murine single-chain Fv antibody-that means if a patient rejects one product, she or he is unlikely to respond to the other two.', 'However, a patient who rejects one CAR T cell may respond to a totally different CAR T cell. For example, a CAR T cell against a different target would be an option, but right now we dont have very many other targets we are using in lymphoma. One option is CD22, so there is the potential of using a totally different CAR construct with a different antibody single-chain Fv, but we have to study this further.', '...the significant toxicity of these therapies, the complexity of its administration, and the logistics surrounding its operation might hinder the commercial uptake and market success of CAR-T therapy. To address these issues, CAR-T manufacturers have assured the FDA that treatment will be limited to highly specialized centers with stem cell transplantation capabilities. Most cancer patients are seen in the community setting,10 thereby community oncologists will play an instrumental role in patient referral and likely determine the initial adoption of this treatment.', 'Currently, CAR T-cell therapy is only considered in experimental settings after exhausting all other treatment options and is thus used as a treatment of last resort']\n"
     ]
    }
   ],
   "source": [
    "\"\"\"\n",
    "KEEP THIS (part2)\n",
    "\"\"\"\n",
    "\n",
    "filepath = 'C:/Users/ianda/Desktop/Dropbox (NSF CORE)/Coding Projects/Python/Webscrape - Sentiment/HCPsentiment2.csv'\n",
    "\n",
    "text2 = []\n",
    "\n",
    "rt = rawText(filepath) # creates a rawText instance\n",
    "print(rt) # I don't understand how this just prints the filepath...\n",
    "\n",
    "for line in rt: # ...and yet, this bit has all the lines in it\n",
    "    text2.append(line)\n",
    "\n",
    "print(text2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Both tisagenlecleucel and axicabtagene ciloleucel carry a black box warning for cytokine-release syndrome (CRS) and for neurologic events. To treat CAR T-cell-induced severe or life-threatening CRS, the FDA expanded the approval of tocilizumab (Actemra) and has required that CAR T-cell therapy be performed only in cancer centers that have completed training in Risk Evaluation and Mitigation Strategy to support its safe use. Currently, about 40 cancer centers are certified to offer CAR T-cell therapy to patients.\n"
     ]
    }
   ],
   "source": [
    "print(text2[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import nltk\n",
    "from nltk import SnowballStemmer, word_tokenize, WordNetLemmatizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "import string\n",
    "\n",
    "errors2 = []\n",
    "\n",
    "for i in range(len(text2)):\n",
    "    for j in range(len(text2[i])):\n",
    "        pair = []\n",
    "        pair.append(i)\n",
    "        if text2[i][j] not in string.printable:\n",
    "            pair.append(j)\n",
    "            errors2.append(pair)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[]\n"
     ]
    }
   ],
   "source": [
    "print(errors2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "for item in errors2:\n",
    "    print(text2[item[0]][item[1]])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "content_cl_sp=[phrase.split() for phrase in content_clean]\n",
    "content_flat = [item for sublist in content_cl_sp for item in sublist]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Both', 'tisagenlecleucel', 'and', 'axicabtagene', 'ciloleucel', 'carry', 'a', 'black', 'box', 'warning', 'for', 'cytokine-release', 'syndrome', '(CRS)', 'and', 'for', 'neurologic', 'events.', 'To', 'treat', 'CAR', 'T-cell-induced', 'severe', 'or', 'life-threatening', 'CRS,', 'the', 'FDA', 'expanded', 'the', 'approval', 'of', 'tocilizumab', '(Actemra)', 'and', 'has', 'required', 'that', 'CAR', 'T-cell', 'therapy', 'be', 'performed', 'only', 'in', 'cancer', 'centers', 'that', 'have', 'completed', 'training', 'in', 'Risk', 'Evaluation', 'and', 'Mitigation', 'Strategy', 'to', 'support', 'its', 'safe', 'use.', 'Currently,', 'about', '40', 'cancer', 'centers', 'are', 'certified', 'to', 'offer', 'CAR', 'T-cell', 'therapy', 'to', 'patients.', 'Weve', 'learned', 'how', 'to', 'grade', '(CRS),', 'weve', 'learned', 'how', 'to', 'treat', 'it,', 'Dr.', 'Grupp', 'said', 'during', 'an', 'FDA', 'advisory', 'committee', 'meeting', 'on', 'Novartis', 'CD19-targeted', 'therapy.', 'And', 'IL-6', 'blockade', 'was', 'really', 'the', 'key.', 'Other', 'so-called', 'neurotoxicities-such', 'as', 'confusion', 'or', 'seizure-like', 'activity-have', 'been', 'seen', 'in', 'most', 'CAR', 'T-cell', 'therapy', 'trials.', 'But', 'in', 'nearly', 'all', 'patients', 'the', 'problem', 'is', 'short', 'lived', 'and', 'reversible,', 'Dr.', 'Brentjens', 'said.', 'There', 'was', 'speculation', 'early', 'on', 'that', 'these', 'neurotoxicities', 'might', 'be', 'related', 'to', 'CRS.', 'But', 'although', 'researchers', 'are', 'still', 'trying', 'to', 'get', 'their', 'hands', 'around', 'the', 'mechanisms,', 'he', 'added,', 'I', 'think', 'most', 'investigators', '(in', 'the', 'field)', 'would', 'agree', 'that', 'theyre', 'distinct', 'from', 'CRS.', 'Furthermore,', 'toxicity', 'is', 'a', 'significant', 'concern', 'with', 'CAR', 'T-cell', 'therapies;', 'severe', 'neurotoxicity', 'has', 'been', 'observed,', 'though', 'the', 'mortality', 'rate', 'for', 'these', 'adverse', 'events', 'remains', 'low,', 'at', 'around', '2%', 'to', '3%', 'across', 'the', 'approximately', '230', 'patients', 'studied', 'so', 'far,', 'said', 'Shah.', 'Interestingly,', 'ALL', 'seems', 'to', 'have', 'a', 'higher', 'rate', 'of', 'neurologic', 'toxicity', 'with', 'CAR', 'T', 'than', 'other', 'cancers', 'do,', 'an', 'observation', 'that', 'suggests', 'that', 'there', 'are', 'some', 'disease', 'features', 'that', 'are', 'linked', 'with', 'adverse', 'events', '(AEs).', 'Adults', 'with', 'ALL', 'appear', 'to', 'have', 'even', 'more', 'neurotoxicity', 'than', 'younger', 'patients.3', 'I', 'have', 'no', 'explanation', 'for', 'this,', 'Shah', 'said.', 'If', 'fever', 'and', 'hypotension', 'do', 'not', 'resolve', 'with', 'tocilizumab,', 'my', 'own', 'personal', 'bias', 'is', 'that', 'more', 'tocilizumab', 'wont', 'help,', 'said', 'Shah,', 'who', 'would', 'resort', 'to', 'steroids', 'in', 'this', 'case.', 'Theyre', 'bad,', 'but', 'theyre', 'not', 'that', 'bad.', 'He', 'urged', 'clinicians', 'not', 'to', 'be', 'afraid', 'to', 'put', 'a', 'patient', 'on', 'steroids', 'as', 'long', 'as', 'they', 'are', 'willing', 'to', 'stop', 'the', 'course', 'once', 'CRS', 'symptoms', 'start', 'to', 'improve.', 'Cerebral', 'edema', 'is', 'another', 'challenging', 'AE,', 'and', 'the', 'answer', 'is', 'nobody', 'knows', 'why', 'cerebral', 'edema', 'was', 'observed', 'among', '6', 'patients', 'treated', 'in', 'Junos', 'trial', 'of', 'its', 'proposed', 'CAR', 'T-cell', 'therapy,', 'JCAR015,', 'which', 'resulted', 'in', 'multiple', 'deaths.', 'The', 'mechanisms', 'of', 'this', 'AE', 'remain', 'elusive.', 'We', 'worry', 'not', 'only', 'about', 'the', 'associated', 'chemotherapy', 'side', 'effects-nausea,', 'vomiting,', 'hair', 'loss-because', 'they', 'do', 'get', 'some', 'low-dose', 'chemotherapy', 'prior', 'to', 'getting', 'CAR', 'T', 'cells,', 'but', 'the', 'unique', 'side', 'effects', 'we', 'recognize', 'with', 'CAR', 'T', 'cells', 'include', 'CRS', 'and', 'neurological', 'toxicities.', 'The', 'CRS', 'can', 'be,', 'in', 'some', 'mild', 'cases,', 'characterized', 'by', 'fevers,', 'chills,', 'slightly', 'low', 'blood', 'pressure', 'that', 'responds', 'to', 'intravenous', 'fluids', 'to,', 'in', 'extreme', 'cases,', 'fevers', 'that', 'are', 'very', 'high,', 'and', 'blood', 'pressure', 'that', 'drops', 'low', 'enough', 'to', 'require', 'medication.', 'In', 'terms', 'of', 'neurological', 'toxicity,', 'some', 'patients', \"don't\", 'have', 'any.', 'Others', 'might', 'have', 'mild', 'confusion.', 'In', 'the', 'severe', 'extreme,', 'patients', 'can', 'become', 'comatose', 'or', 'have', 'seizures', 'as', 'a', 'result', 'of', 'neurotoxicity.', 'Thus', 'far,', 'the', 'companies', 'have', 'been', 'very', 'careful', 'in', 'terms', 'of', 'having', 'sites', 'that', 'have', 'experience', 'and', 'adequate', 'training', 'to', 'treat', 'patients.', \"They're\", 'limiting', 'the', 'first', 'roll-out', 'to', 'sites', 'that', 'are', 'able', 'to', 'manage', 'these', 'toxicities,', 'because', 'it', 'is', 'a', 'multimodality', 'management.', 'Questions', 'about', 'toxicity', 'centered', 'on', 'how', 'optimal', 'management', 'should', 'be', 'delivered.', 'Over', '60%', 'suggested', 'that', 'patients', 'should', 'be', 'monitored', 'for', '1', 'to', '2', 'weeks', 'after', 'administration.', 'Notably,', 'one-third', 'stated', 'that', 'toxicity', 'might', 'hinder', 'their', 'prescribing', 'of', 'CAR-T', 'therapy.', 'Additionally,', 'the', 'side-effects', 'of', 'immunotherapy', 'can', 'overshadow', 'clinical', 'benefits,', 'and', 'CAR', 'T-cell', 'therapy', 'is', 'proving', 'to', 'be', 'particularly', 'challenging:', 'for', 'example,', '95%', 'of', 'patients', 'treated', 'with', 'axicabtagene', 'ciloleucel', 'had', 'adverse', 'events', 'of', 'grade', '3', 'or', 'worse,', 'including', 'haematological', 'and', 'neurological', 'toxicities.', 'When', 'asked', 'about', 'published', 'information', 'from', 'clinical', 'trials,', 'almost', 'half', 'of', 'the', 'participants', 'were', 'not', 'familiar', 'with', 'the', 'efficacy', 'and', 'toxicity', 'data', 'on', 'CAR-T', 'therapy.', 'Despite', 'most', 'respondents', 'labeling', 'CAR-T', 'therapy', 'as', 'a', 'potentially', 'game-changing', 'approach,', 'only', '20%', 'had', 'ever', 'referred', 'a', 'patient', 'to', 'a', 'CAR-T', 'clinical', 'trial', 'Our', 'study', 'highlights', 'several', 'findings', 'that', 'are', 'critical', 'to', 'all', 'stakeholders.', 'First', 'and', 'foremost,', 'lack', 'of', 'familiarity', 'with', 'published', 'data', 'might', 'be', 'predictable', 'since', 'studies', 'were', 'conducted', 'in', 'refractory', 'diseases', 'that', 'are', 'commonly', 'treated', 'at', 'academic', 'sites.', 'Overcoming', 'this', 'educational', 'barrier', 'can', 'be', 'achieved', 'through', 'data', 'dissemination,', 'webinars,', 'regional', 'symposia,', 'and', 'other', 'venues.', 'When', 'queried', 'on', 'how', 'their', 'prescribing', 'habits', 'might', 'evolve', 'should', 'CAR-T', 'therapies', 'become', 'FDA', 'approved', 'for', 'indications', 'studied', 'in', 'ongoing', 'and', 'completed', 'clinical', 'trials;', 'only', '22%', 'suggested', 'they', 'are', 'unlikely', 'to', 'prescribe', 'CAR-T', 'therapy.', 'Lastly,', 'we', 'inquired', 'about', 'barriers', 'to', 'successful', 'CAR-T', 'implementation;', 'the', 'logistics', 'of', 'administration', 'was', 'the', 'most', 'common', 'barrier,', 'followed', 'by', 'the', 'known', 'and', 'perceived', 'toxicities', 'While', 'the', 'majority', 'believed', 'that', 'medical', 'oncologists', 'should', 'oversee', 'the', 'management', 'of', 'CAR-T-treated', 'patients,', '22%', 'believed', 'that', 'engaging', 'critical', 'care', 'physicians', 'will', 'be', 'essential', 'for', 'optimal', 'care', 'We', 'have', 'reported', 'on', 'the', 'very', 'high', 'response', 'rates', 'and', 'durable', 'remission', 'rates', 'in', 'patients', 'with', 'ALL.', 'We', 'have', 'treated', 'more', 'than', '300', 'patients', 'with', 'tisagenlecleucel', 'in', 'clinical', 'trials,', 'and', 'a', 'lot', 'of', 'that', 'information', 'was', 'used', 'for', 'FDA', 'approval', 'of', 'the', 'therapy.', 'Dr.', 'Lonial:', 'In', 'my', 'experience', 'treating', 'patients', 'with', 'multiple', 'myeloma,', 'the', 'benefit', 'from', 'this', 'therapy', 'has', 'been', 'quite', 'striking.', 'In', 'a', 'small', 'clinical', 'study', 'of', 'a', 'second-generation', 'CAR', 'construct', 'targeting', 'the', 'B-cell', 'maturation', 'antigen', '(BCMA)', 'in', 'multiple', 'myeloma,', 'the', 'overall', 'response', 'rates', 'looked', 'even', 'better', 'than', 'what', 'weve', 'seen', 'with', 'CD19', 'in', 'lymphoma', 'and', 'ALL.6', 'Now,', 'these', 'are', 'very,', 'very', 'early', 'days,', 'but', 'I', 'think', 'the', 'responses', 'in', 'durability', 'are', 'going', 'to', 'be', 'quite', 'impressive.', 'Dr.', 'Maloney:', 'We', 'have', 'also', 'published', 'extensively', 'on', 'our', 'clinical', 'trials', 'data', 'in', 'chronic', 'lymphocytic', 'leukemia', '(CLL),', 'lymphoma,', 'and', 'ALL,', 'and', 'there', 'is', 'clearly', 'a', 'high', 'initial', 'response', 'rate', 'with', 'CAR', 'T-cell', 'therapy.', 'We', 'are', 'seeing', 'remission', 'rates', 'in', 'patients', 'in', 'whom', 'we', 'did', 'not', 'see', 'any', 'type', 'of', 'remission', 'with', 'conventional', 'therapies.', 'Some', 'patients', 'relapse,', 'and', 'we', 'dont', 'know', 'whether', 'patients', 'are', 'cured', 'yet,', 'and', 'there', 'can', 'be', 'serious', 'toxicities', 'with', 'this', 'therapy.', 'Patients', 'undergoing', 'CAR', 'T-cell', 'therapy', 'require', 'leukapheresis,', 'administration', 'of', 'chemotherapy', 'for', 'depletion', 'of', 'lymphocytes', 'and', 'administration', 'of', 'CAR', 'T-cell', 'therapy,', 'and', 'a', 'high', 'proportion', 'of', 'patients', 'receiving', 'CAR', 'T-cell', 'therapy', 'require', 'ICU', 'hospitalizations', 'for', 'cytokine', 'release', 'syndrome,', 'a', 'severe', 'but', 'common', 'side', 'effect', 'of', 'CAR', 'T-cell', 'therapy,', 'Hernandez', 'told', 'HemOnc', 'Today.', 'All', 'of', 'this', 'is', 'related', 'with', 'facility', 'costs', '-', 'costs', 'reimbursed', 'to', 'the', 'hospital', '-', 'and', 'physician', 'costs,', 'which,', 'again,', 'are', 'not', 'accounted', 'for', 'by', 'the', 'price', 'tag', 'announced', 'by', 'the', 'manufacturer.', 'setting,10', 'thereby', 'community', 'oncologists', 'will', 'play', 'an', 'instrumental', 'role', 'in', 'patient', 'referral', 'and', 'likely', 'determine', 'the', 'initial', 'adoption', 'of', 'this', 'treatment.', 'Patients', 'undergoing', 'CAR', 'T-cell', 'therapy', 'require', 'leukapheresis,', 'administration', 'of', 'chemotherapy', 'for', 'depletion', 'of', 'lymphocytes', 'and', 'administration', 'of', 'CAR', 'T-cell', 'therapy,', 'and', 'a', 'high', 'proportion', 'of', 'patients', 'receiving', 'CAR', 'T-cell', 'therapy', 'require', 'ICU', 'hospitalizations', 'for', 'cytokine', 'release', 'syndrome,', 'a', 'severe', 'but', 'common', 'side', 'effect', 'of', 'CAR', 'T-cell', 'therapy,', 'Hernandez', 'told', 'HemOnc', 'Today.', 'All', 'of', 'this', 'is', 'related', 'with', 'facility', 'costs', '-', 'costs', 'reimbursed', 'to', 'the', 'hospital', '-', 'and', 'physician', 'costs,', 'which,', 'again,', 'are', 'not', 'accounted', 'for', 'by', 'the', 'price', 'tag', 'announced', 'by', 'the', 'manufacturer.', 'It', 'is', 'important', 'to', 'quantify', 'the', 'total', 'costs', 'of', 'this', 'therapy', 'because', 'these', 'nondrug', 'costs', 'are', 'certainly', 'not', 'negligible.', 'It', 'is', 'important', 'to', 'account', 'for', 'them', 'when', 'doing', 'pharmacoeconomic', 'evaluations', 'of', 'these', 'therapies', 'and', 'deciding', 'on', 'their', 'coverage,', 'Hernandez', 'said.', 'Moreover,', 'the', 'outcomes-based', 'agreements', 'announced', 'for', 'tisagenlecleucel', 'would', 'only', 'refund', 'pharmaceutical', 'costs', 'for', 'nonresponders.', 'So,', 'it', 'would', 'be', 'important,', 'as', 'well,', 'to', 'account', 'for', 'those', 'nondrug', 'costs', 'when', 'payers', 'negotiate', 'pricing', 'agreements', 'with', 'manufacturers.', 'The', 'researchers', 'used', 'the', 'sum', 'of', 'the', 'expected', 'costs', 'in', 'each', 'scenario', 'and', 'the', 'probability', 'of', 'each', 'scenario', 'to', 'determine', 'the', 'mean', 'expected', 'cost', 'per', 'patient.', 'The', 'mean', 'total', 'expected', 'cost', 'of', 'tisagenlecleucel', 'was', '$510,963.', 'Costs', 'ranged', 'from', '$478,777', 'for', 'patients', 'who', 'did', 'not', 'develop', 'cytokine', 'release', 'syndrome', 'to', '$531,813', 'for', 'patient', 'who', 'did', 'develop', 'cytokine', 'release', 'syndrome.', 'The', 'mean', 'total', 'expected', 'cost', 'decreased', 'to', '$432,131', 'for', 'tisagenlecleucel', 'when', 'researchers', 'adjusted', 'for', 'the', 'outcomes-based', 'pricing', 'arrangement', 'announced', 'by', 'Novartis.', 'Every', 'year', 'about', '600', 'U.S.', 'patients', 'are', 'eligible', 'for', 'tisagenlecleucel.', 'Using', 'the', 'mean', 'total', 'expected', 'cost,', 'the', 'researchers', 'estimated', 'the', 'annual', 'expenditure', 'would', 'be', '$259', 'million.', 'The', 'mean', 'total', 'expected', 'cost', 'of', 'axicabtagene', 'ciloleucel', 'was', '$402,647.', 'With', '7,500', 'U.S.', 'patients', 'eligible', 'for', 'axicabtagene', 'ciloleucel,', 'the', 'estimated', 'annual', 'expenditure', 'would', 'be', '$3', 'billion.', 'Nondrug', 'costs', 'accounted', 'for', '7%', 'of', 'total', 'costs.', 'However,', 'this', 'doesnt', 'mean', 'that', 'these', 'costs', 'are', 'negligible,', 'because', 'this', '7%', 'accounts', 'for', '$30,000', 'for', 'the', 'average', 'patient', 'and', 'up', 'to', '$60,000', 'for', 'those', 'who', 'present', 'with', 'cytokine', 'release', 'syndrome,', 'Hernandez', 'said.', 'However,', 'although', 'these', 'promising', 'findings', 'are', 'generating', 'much', 'enthusiasm', 'for', 'CAR', 'T-cell', 'therapy-ASCO', 'named', 'adoptive-cell', 'immunotherapy', 'its', '2018', 'Advance', 'of', 'the', 'Year4-it', 'is', 'tempered', 'by', 'their', 'hefty', 'price', 'tags:', '$475,000', 'for', 'tisagenlecleucel', 'and', '$373,000', 'for', 'axicabtagene', 'ciloleucel.', 'And', 'these', 'prices', 'reflect', 'just', 'the', 'cost', 'of', 'extracting', 'a', 'patients', 'T', 'cells,', 'engineering', 'them', 'to', 'produce', 'CARs', 'on', 'the', 'surface', 'of', 'the', 'cells,', 'and', 'infusing', 'the', 'cells', 'back', 'into', 'the', 'patient.', 'They', 'do', 'not', 'include', 'fees', 'for', 'hospital', 'stays,', 'supportive', 'care,', 'or', 'physician', 'visits,', 'which', 'could', 'drive', 'the', 'total', 'cost', 'to', 'stratospheric', 'levels', 'of', 'more', 'than', '$1', 'million', 'per', 'patient,', 'according', 'to', 'some', 'reports.', 'These', 'drugs', 'are', 'very', 'expensive.', 'The', 'ALL', 'product', 'costs', 'about', '$475,000', 'and', 'the', 'DLBCL', 'products', 'cost', 'about', '$375,000,', 'Deol,', 'associate', 'professor', 'with', 'Karmanos', 'Cancer', 'Institute,', 'said.', 'That', 'is', 'just', 'the', 'cost', 'of', 'the', 'cells.', 'This', 'does', 'not', 'include', 'the', 'management', 'of', 'toxicities,', 'and', \"it's\", 'not', 'out', 'of', 'the', 'ordinary', 'for', 'the', \"patient's\", 'total', 'bill', 'to', 'be', 'close', 'to', '$500,000', 'when', \"they're\", 'done', 'with', 'treatment.', 'There', 'needs', 'to', 'be', 'a', 'little', 'more', 'research', 'into', 'making', 'this', 'treatment', 'more', 'affordable', 'so', 'that', 'more', 'patients', 'can', 'be', 'treated.', 'Cost', 'did', 'not', 'appear', 'to', 'be', 'a', 'hindrance', 'to', 'prescribing,', 'as', 'most', 'believed', 'CAR-T', 'would', 'be', 'cost-effective', 'if', 'priced', 'at', 'parity', 'with', 'allogeneic', 'stem', 'cell', 'transplantation.', 'The', 'key', 'driver', 'of', 'the', 'NICE', 'and', 'NHS', 'England', 'decisions', 'has', 'been', 'cost.', 'Axicabtagene', 'ciloleucel', 'is', 'believed', 'to', 'cost', 'more', 'than', 'GBP50?000', 'per', 'quality-adjusted', 'life-year', '(QALY)', 'gained,', 'which', 'is', 'at', 'the', 'upper', 'limit', 'of', 'tolerance', 'for', 'cancer', 'treatments.', 'The', 'manufacturer', 'has', 'proposed', 'a', 'commercial', 'arrangement', 'that', 'might', 'sway', 'the', 'eventual', 'decision', 'in', 'favour', 'of', 'approval,', 'although', 'at', 'the', 'time', 'of', 'writing,', 'NICE', 'has', 'requested', 'the', 'manufacturer', 'find', 'more', 'UK', 'data', 'from', 'which', 'a', 'comparison', 'with', 'the', 'current', 'standard', 'of', 'care', 'can', 'be', 'made.', 'Tisagenlecleucel,', 'by', 'contrast,', 'which', 'is', 'presumably', 'costing', 'less', 'than', 'the', 'GBP282?000', 'list', 'price', 'in', 'the', 'arrangement', 'secured', 'by', 'NHS', 'England,', 'might', 'have', 'a', 'more', 'favourable', 'cost', 'per', 'QALY', 'because', 'children', 'have', 'a', 'longer', 'life', 'expectancy', 'than', 'older', 'patients,', 'provided', 'toxicities', 'are', 'manageable', 'and', 'not', 'debilitating.', 'This', 'past', 'April,', 'the', 'Centers', 'for', 'Medicare', 'and', 'Medicaid', '(CMS)', 'said', 'it', 'would', 'reimburse', 'hospitals', 'about', '$400,000', 'for', 'axicabtagene', 'ciloleucel', 'and', '$500,000', 'for', 'tisagenlecleucel.', 'Although', 'outpatients', 'usually', 'have', 'a', '20%', 'copayment', 'on', 'Medicare', 'B', 'services,', 'which', 'would', 'mean', 'a', 'copayment', 'of', '$79,076', 'for', 'axicabtagene', 'ciloleucel', 'and', '$100,168', 'for', 'tisagenlecleucel,', 'the', 'Social', 'Security', 'Act', 'statute', 'requires', 'CMS', 'to', 'cap', 'outpatient', 'copayments', 'at', 'the', 'amount', 'of', 'the', 'inpatient', 'deductible,', 'which', 'is', '$1,340', 'in', '2018.', 'When', 'tisagenlecleucel', 'was', 'approved', 'in', 'August', '2017,', 'Novartis', 'made', 'an', 'outcomes-based', 'agreement', 'with', 'the', 'CMS,', 'which', 'calls', 'for', 'payment', 'to', 'the', 'company', 'for', 'patients', 'who', 'show', 'a', 'morphologic', 'remission', 'within', 'a', 'month', 'after', 'receiving', 'their', 'CAR', 'T-cell', 'infusion.', 'If', 'the', 'patient', 'does', 'not', 'respond', 'within', 'the', 'first', 'month-a', 'majority', 'of', 'patients,', 'about', '80%,', 'have', 'an', 'initial', 'response', 'to', 'the', 'therapy-Novartis', 'will', 'not', 'bill', 'those', 'medical', 'facilities', 'that', 'opted', 'in', 'to', 'the', 'outcomes-based', 'agreement.', 'Importantly,', 'most', 'prescribers', '(46%)', 'plan', 'on', 'referring', 'their', 'patients', 'to', 'large', 'academic', 'centers,', 'while', 'one-third', 'would', 'rather', 'treat', 'some', 'of', 'their', 'patients', 'locally', 'while', 'referring', 'others', 'to', 'academic', 'sites', 'Physicians', 'appear', 'receptive', 'to', 'prescribing', 'CAR-T', 'therapy', 'once', 'regulatory', 'approval', 'is', 'granted,', 'but', 'there', 'was', 'no', 'consensus', 'as', 'to', 'their', 'desire', 'on', 'where', 'treatment', 'should', 'be', 'delivered.', 'While', 'almost', 'half', 'of', 'the', 'respondents', 'suggested', 'that', 'all', 'eligible', 'CAR-T', 'patients', 'should', 'be', 'referred', 'to', 'academic', 'centers,', 'one-third', 'stated', 'that', 'they', 'will', 'refer', 'some', 'but', 'not', 'all', 'of', 'their', 'CAR-T', 'eligible', 'patients.', 'Fewer', 'physicians', 'voiced', 'their', 'willingness', 'to', 'treat', 'these', 'patients', 'locally', 'if', 'allowed', 'by', 'payers', 'and', 'manufacturers.', 'This', 'might', 'be', 'problematic', 'as', 'CAR-T', 'therapy', 'requires', 'highly', 'specialized', 'centers', 'with', 'allogeneic', 'stem', 'cell', 'transplantation', 'capabilities', 'given', 'the', 'uniqueness', 'of', 'observed', 'toxicities.12', 'While', 'it', 'is', 'unlikely', 'that', 'CAR-T', 'therapy', 'will', 'be', 'given', 'at', 'community', 'sites', 'at', 'launch,', 'this', 'might', 'change', 'in', 'the', 'future.', 'Additional', 'logistical', 'challenges', 'were', 'suggested', 'as', 'major', 'hurdles', 'for', 'CAR-T', 'therapy', 'adoption.', 'Community', 'oncologists', 'voiced', 'their', 'concerns', 'about', 'the', 'operational', 'complexity', 'and', 'the', 'fact', 'that', 'successful', 'CAR-T', 'administration', 'requires', 'harmonized', 'collaboration', 'between', 'the', 'treating', 'facility,', 'manufacturers,', 'and', 'the', 'transportation', 'system.', 'Aligning', 'these', 'stakeholders', 'to', 'assure', 'timely', 'apheresis,', 'collection,', 'transportation,', 'T-cell', 'expansion,', 'and', 'reinfusion', 'might', 'be', 'challenging,', 'especially', 'as', 'eligible', 'patients', 'are', 'often', 'sick,', 'with', 'active', 'disease,', 'and', 'receiving', 'lymphodepleting', 'chemotherapy', 'prior', 'to', 'the', 'infusion.', 'Dr.', 'June:', 'Theoretically,', 'like', 'a', 'lot', 'of', 'biologic', 'therapies,', 'it', 'will', 'be', 'best', 'to', 'use', 'cellular', 'immunotherapies', 'early', 'in', 'the', 'course', 'of', 'a', 'disease,', 'but', 'that', 'will', 'require', 'randomized', 'clinical', 'trials', 'to', 'know', 'for', 'sure.', 'There', 'is', 'a', 'clinical', 'study', 'scheduled', 'to', 'begin', 'this', 'year', 'testing', 'CAR', 'T', 'cells', 'upfront', 'in', 'high-risk', 'patients', 'with', 'pre-B', 'cell', 'ALL,', 'so', 'we', 'should', 'have', 'more', 'information', 'soon.', 'Dr.', 'Lonial:', 'Im', 'not', 'a', 'lymphoma', 'expert,', 'but', 'with', 'all', 'the', 'new', 'therapies,', 'when', 'you', 'are', 'not', 'certain', 'as', 'to', 'where', 'the', 'risks', 'and', 'benefits', 'are', 'going', 'to', 'fall', 'out,', 'it', 'is', 'usually', 'best', 'to', 'treat', 'the', 'sickest', 'patients', 'with', 'the', 'fewest', 'options', 'early', 'on.', 'There', 'are', 'subsets', 'of', 'patients', 'with', 'lymphoma', 'who', 'do', 'quite', 'well', 'with', 'standard', 'chemotherapy,', 'so', 'the', 'real', 'question', 'to', 'me', 'is', 'can', 'we', 'identify', 'the', 'high-risk', 'group', 'of', 'patients', 'before', 'they', 'relapse', 'and', 'expose', 'them', 'to', 'CAR', 'T-cell', 'therapy', 'earlier', 'in', 'the', 'course', 'of', 'disease,', 'after', 'first', 'relapse.', 'For', 'instance,', 'in', 'the', 'context', 'of', 'relapsed', 'large', 'B-cell', 'lymphoma,', 'is', 'a', 'CAR', 'T-cell', 'option', 'better', 'than', 'an', 'autologous', 'transplant?', 'There', 'are', 'clinical', 'studies', 'under', 'way', 'to', 'answer', 'these', 'questions,', 'but', 'well', 'have', 'to', 'wait', 'for', 'the', 'data', 'to', 'know', 'for', 'sure.', 'Dr.', 'Maloney:', 'Cell', 'immunotherapies', 'are', 'not', 'going', 'to', 'be', 'immediately', 'moved', 'to', 'the', 'upfront', 'setting,', 'but', 'the', 'next', 'studies', 'in', 'lymphoma', 'will', 'compare', 'CAR', 'T', 'cells', 'with', 'standard', 'of', 'care', 'for', 'first-relapse', 'disease,', 'which', 'is', 'autologous', 'stem', 'cell', 'transplant.', 'To', 'move', 'CAR', 'T-cell', 'therapy', 'to', 'the', 'actual', 'front-line', 'setting', 'is', 'going', 'to', 'require', 'more', 'work,', 'at', 'least', 'in', 'lymphoma,', 'because', 'the', 'results', 'are', 'good', 'with', 'conventional', 'chemotherapy', 'for', 'most', 'patients.', 'But', 'as', 'soon', 'as', 'conventional', 'chemotherapy', 'does', 'not', 'work', 'in', 'the', 'front-line', 'setting,', 'I', 'can', 'certainly', 'envision', 'a', 'time', 'when', 'CAR', 'T', 'cells', 'would', 'be', 'second-line', 'standard', 'of', 'care.', 'Were', 'not', 'quite', 'there', 'yet,', 'but', 'it', 'will', 'happen.', 'Mr.', 'Touchon:', 'We', 'believe', 'there', 'is', 'a', 'place', 'for', 'this', 'therapy', 'in', 'the', 'earlier', 'treatment', 'setting,', 'but', 'we', 'need', 'to', 'prove', 'it', 'is', 'appropriate', 'in', 'specific', 'clinical', 'studies.', 'We', 'are', 'planning', 'a', 'study', 'this', 'year', 'with', 'tisagenlecleucel', 'in', 'patients', 'with', 'DLBCL', 'after', 'first', 'relapse', 'and', 'also', 'a', 'small', 'trial', 'of', 'tisagenlecleucel', 'in', 'the', 'first-line', 'setting', 'in', 'very', 'high-risk', 'pediatric', 'patients', 'with', 'B-cell', 'ALL.', 'Additional', 'analysis', 'of', 'data', 'from', 'the', 'ELIANA', 'clinical', 'trial', 'shows', 'impressive', 'results', 'in', '75', 'patients', 'treated', 'with', 'tisagenlecleucel.', 'The', 'analysis', 'found', 'the', 'overall', 'remission', 'rate', 'within', '3', 'months', 'was', '81%;', 'the', 'rates', 'of', 'event-free', 'survival', 'were', '73%', 'at', '6', 'months', 'and', '50%', 'at', '12', 'months;', 'overall', 'survival', 'was', '90%', 'and', '76%', 'over', 'the', 'same', 'time', 'intervals.', 'Follow-up', 'analysis', 'of', 'results', 'from', 'the', 'ZUMA-1', 'trial', 'investigating', 'the', 'effectiveness', 'of', 'axicabtagene', 'ciloleucel', 'in', 'patients', 'with', 'refractory', 'NHL', 'also', 'shows', 'impressive', 'outcomes.', 'According', 'to', 'the', 'analysis,', 'more', 'than', '1', 'year', 'after', 'treatment,', '42%', 'of', 'the', '108', 'patients', 'enrolled', 'in', 'the', 'trial', 'had', 'maintained', 'remission,', 'and', '40%', 'of', 'the', 'patients', 'exhibited', 'no', 'evidence', 'of', 'cancer.', 'In', 'addition,', 'more', 'than', 'half', 'of', 'the', 'patients', 'were', 'alive', 'at', 'the', 'median', 'follow-up', 'of', '15.4', 'months-more', 'than', 'double', 'the', 'median', 'survival', 'of', '6.6', 'months', 'for', 'patients', 'treated', 'with', 'conventional', 'therapy.', 'The', 'progress', 'made', 'with', 'CAR', 'T-cell', 'therapy', 'in', 'children', 'with', 'ALL', 'has', 'been', 'fantastic,', 'said', 'Terry', 'Fry,', 'M.D.,', 'a', 'lead', 'investigator', 'on', 'several', 'POB', 'trials', 'of', 'CAR', 'T', 'cells.', 'CD19-targeted', 'CAR', 'T', 'cells', 'were', 'initially', 'tested', 'in', 'adults.', 'But', 'the', 'fact', 'that', 'the', 'first', 'approval', 'is', 'for', 'a', 'therapy', 'for', 'children', 'and', 'adolescents', 'with', 'ALL', 'is', 'a', 'watershed', 'moment,', 'Dr.', 'Fry', 'continued.', 'Our', 'data', 'provide', 'the', 'first', 'true', 'glimpse', 'of', 'the', 'potential', 'of', 'this', 'approach', 'in', 'patients', 'with', 'aggressive', 'lymphomas,', 'who,', 'until', 'this', 'point,', 'were', 'virtually', 'untreatable,', 'said', 'the', 'trials', 'lead', 'investigator,', 'James', 'Kochenderfer,', 'M.D.,', 'of', 'the', 'NCI', 'Experimental', 'Transplantation', 'and', 'Immunology', 'Branch.', 'The', 'results', 'in', 'lymphoma', 'to', 'date', 'have', 'been', 'incredibly', 'successful,', 'Dr.', 'Kochenderfer', 'said,', 'and', 'CAR', 'T', 'cells', 'are', 'almost', 'certain', 'to', 'become', 'a', 'frequently-used', 'therapy', 'for', 'several', 'types', 'of', 'lymphoma.', 'First,', 'said', 'Shah,', 'Adult', 'ALL', 'doesnt', 'get', 'enough', 'attention,', 'but', 'it', 'does', 'account', 'for', 'nearly', 'half', 'of', 'all', 'the', 'all', 'cases', 'that', 'we', 'see.', 'Adult', 'patients', 'with', 'ALL', 'are', 'more', 'likely', 'to', 'relapse,', 'and', 'their', 'outcomes', 'are', 'typically', 'poor,', 'with', 'an', 'average', 'survival', 'of', 'roughly', '40%.', 'I', 'think', 'we', 'have', 'a', 'lot', 'of', 'room', 'for', 'improvement', 'there,', 'said', 'Shah.', 'Allogenic', 'transplant', 'may', 'help', 'these', 'patients,', 'and', 'while', 'inotuzumab', 'does', 'improve', 'overall', 'survival,', 'its', 'not', 'easy', 'to', 'get', 'excited', 'about', 'long-term', 'survival', 'improvements', 'of', 'only', 'small', 'percentages.', 'With', 'blinatumomab,', 'a', 'T-cell', 'directed', 'therapy,', 'We', 'did', 'better', 'than', 'chemotherapy', 'for', 'a', 'short', 'while,', 'Shah', 'explained;', 'however,', 'even', 'with', 'blinatumomab,', 'long-term', 'survival', 'remains', 'around', '25%,', 'so', 'were', 'still', 'having', 'trouble', 'getting', 'past', 'this', 'hurdle.', 'In', 'addition', 'to', 'the', 'challenge', 'posed', 'by', 'manufacturing', 'time,', 'data', 'also', 'show', 'that', 'adults', 'had', 'worse', 'outcomes', 'than', 'children', 'when', 'treated', 'with', 'tisagenlecleucel,1', 'and', 'Thats', 'disconcerting', 'as', 'we', 'decrease', 'the', 'age', 'we', 'see', 'better', 'responses.', 'This', 'is', 'discouraging', 'for', 'adult', 'patients;', 'We', 'are', 'absolutely', 'improving', 'survival,', 'said', 'Shah,', 'but', 'Why', 'do', 'adults', 'have', 'to', 'take', 'the', 'short', 'end', 'of', 'the', 'stick?', 'The', 'reason', 'these', 'products', 'were', 'approved', 'was', 'based', 'on', 'results', 'of', 'clinical', 'trials.', 'ZUMA-1', '(with', 'axi-cel)', 'looked', 'at', 'relapsed/refractory', 'DLBCL', 'and', 'the', 'overall', 'response', 'rate', 'was', 'close', 'to', '80%.', 'However,', 'the', 'complete', 'response', '(CR)', 'rate', 'around', '12', 'to', '18', 'months', 'is', 'approximately', '40%', 'to', '45%.', 'There', 'are', 'patients', 'who', 'respond,', 'but', 'unfortunately', 'did', 'relapse', 'after', 'treatment.', 'Therefore,', 'there', 'needs', 'to', 'be', 'more', 'research', 'into', 'preventing', 'relapse', 'and', 'keeping', 'these', 'patients', 'in', 'remission.', 'Tisagenlecleucel', 'was', 'also', 'explored', 'in', 'a', 'multicenter', 'study', 'that', 'looked', 'at', 'a', 'few', 'hundred', 'patients', 'who', 'were', 'treated', 'with', 'the', 'product;', 'their', 'response', 'rates', 'were', 'around', '55%', 'to', '60%', 'with,', 'again,', 'long-term', 'CR', 'rates', 'in', 'the', '40%', 'to', '45%', 'range.', 'We', 'have', 'seen', 'some', 'differences', 'in', 'terms', 'of', 'the', 'upfront', 'responses,', 'but', 'if', 'you', 'look', 'at', 'the', 'long-term', 'CR', 'data', 'for', 'both', 'studies,', 'they', 'seem', 'to', 'be', 'similar', 'in', 'the', '40%', 'to', '50%', 'range.', 'The', 'main', 'issue', 'regarding', 'these', 'decisions', 'is', 'whether', 'CAR', 'T-cell', 'therapy', 'is', 'more', 'effective', 'than', 'current', 'standard', 'of', 'care-and', 'therein', 'lies', 'a', 'problem.', 'There', 'are', 'no', 'prospective,', 'head-to-head', 'comparisons', 'with', 'existing', 'care.', 'Currently,', 'CAR', 'T-cell', 'therapy', 'is', 'only', 'considered', 'in', 'experimental', 'settings', 'after', 'exhausting', 'all', 'other', 'treatment', 'options', 'and', 'is', 'thus', 'used', 'as', 'a', 'treatment', 'of', 'last', 'resort,', 'limiting', 'the', 'available', 'evidence.', 'In', 'the', 'UK,', 'only', '200', 'of', 'about', '5000', 'people', 'diagnosed', 'each', 'year', 'with', 'diffuse', 'large', 'B-cell', 'lymphoma', 'or', 'primary', 'mediastinal', 'large', 'B-cell', 'lymphoma', 'might', 'be', 'eligible', 'for', 'CAR', 'T-cell', 'therapy,', 'and', 'only', '15-20', 'of', '400', 'children', 'each', 'year', 'with', 'acute', 'lymphoblastic', 'leukaemia.', 'The', 'current', 'evidence', 'for', 'axicabtagene', 'ciloleucel', 'is', 'from', 'a', 'phase', '2', 'trial', 'of', '101', 'patients', 'with', 'refractory', 'disease,', 'which', 'showed', 'an', 'objective', 'response', 'of', '82%.', 'For', 'tisagenlecleucel,', 'a', 'non-comparative,', 'phase', '1-2', 'trial', 'of', '75', 'patients,', 'reported', 'a', 'remission', 'within', '3', 'months', 'of', '81%.', 'Taken', 'alone,', 'these', 'results', 'seem', 'promising,', 'but', 'the', 'lack', 'of', 'control', 'group', 'in', 'both', 'trials', 'and', 'the', 'choice', 'of', 'surrogate', 'primary', 'endpoints', 'make', 'the', 'benefits', 'difficult', 'to', 'discern.', 'But', 'there', 'is', 'still', 'more', 'to', 'do', 'with', 'existing', 'CAR', 'T-cell', 'therapies,', 'Dr.', 'Fry', 'said.', 'He', 'is', 'particularly', 'enthusiastic', 'about', 'the', 'potential', 'to', 'use', 'CAR', 'T', 'cells', 'earlier', 'in', 'the', 'treatment', 'process', 'for', 'children', 'with', 'ALL,', 'specifically', 'those', 'who', 'are', 'at', 'high', 'risk', '(based', 'on', 'specific', 'clinical', 'factors)', 'of', 'their', 'disease', 'returning', 'after', 'their', 'initial', 'chemotherapy,', 'which', 'typically', 'is', 'given', 'for', 'approximately', '2', 'and', 'a', 'half', 'years.', 'In', 'this', 'scenario,', 'he', 'explained,', 'if', 'early', 'indicators', 'suggested', 'that', 'these', 'high-risk', 'patients', 'werent', 'having', 'an', 'optimal', 'response', 'to', 'chemotherapy,', 'it', 'could', 'be', 'stopped', 'and', 'the', 'patients', 'could', 'be', 'treated', 'with', 'CAR', 'T', 'cells.', 'For', 'patients', 'who', 'respond', 'well,', 'they', 'could', 'be', 'spared', '2', 'more', 'years', 'of', 'chemotherapy,', 'Dr.', 'Fry', 'said.', 'Thats', 'amazing', 'to', 'think', 'about.', 'In', 'looking', 'to', 'the', 'future,', 'Shah', 'says', 'that', 'off-the-shelf', 'CAR', 'T-cell', 'therapies', 'will', 'be', 'key', 'to', 'treating', 'more', 'patients,', 'and', 'that', 'improving', 'on', 'current', 'toxicities', 'will', 'be', 'key.', 'Finally,', 'improving', 'the', 'durability', 'of', 'response', 'will', 'be', 'necessary:', 'Post-CAR', 'T', 'relapse', 'is', 'going', 'to', 'be', 'a', 'big', 'problem,', 'and', 'I', 'dont', 'know', 'how', 'to', 'solve', 'it', 'We', 'have', 'to', 'worry', 'about', 'the', 'fact', 'that', 'response', 'isnt', 'durable.', 'Investing', 'in', 'resources', 'that', 'facilitate', 'safe', 'and', 'effective', 'CAR-T', 'therapy', 'in', 'nonacademic', 'entities', 'is', 'an', 'essential', 'strategy', 'for', 'payers', 'and', 'manufacturers', 'to', 'ensure', 'that', 'eligible', 'patients', 'receive', 'this', 'therapy.', 'Travel', 'to', 'academic', 'sites', 'is', 'not', 'always', 'feasible', 'and', 'certainly', 'represents', 'a', 'logistical', 'barrier', 'for', 'any', 'specialized', 'therapy', 'or', 'procedure.13', 'Timely', 'referral', 'and', 'having', 'proper', 'channels', 'between', 'community', 'and', 'academic', 'sites', 'is', 'critical', 'given', 'the', 'seriousness', 'of', 'illnesses', 'that', 'CAR-T', 'are', 'indicated', 'to', 'treat.', '...long-term', 'follow-up', 'data', 'on', 'the', 'safety', 'of', 'these', 'therapies', 'are', 'essential.', 'Mr.', 'Touchon:', 'I', 'agree', 'that', 'cost', 'is', 'an', 'important', 'topic.', 'When', 'we', 'considered', 'the', 'price', 'of', 'tisagenlecleucel', 'in', 'the', 'United', 'States,', 'the', 'first', 'thing', 'we', 'looked', 'at', 'was', 'its', 'medical', 'value', 'and', 'the', 'value', 'it', 'brings', 'to', 'patients,', 'as', 'evidenced', 'by', 'the', 'ELIANA', 'study.', 'Then', 'we', 'looked', 'at', 'the', 'value', 'to', 'the', 'health-care', 'system', 'and', 'society.', 'Many', 'of', 'the', 'patients', 'with', 'ALL', 'treated', 'with', 'tisagenlecleucel', 'were', 'able', 'to', 'resume', 'their', 'normal', 'life,', 'and', 'their', 'parents', 'and', 'caregivers', 'were', 'also', 'able', 'to', 'resume', 'their', 'normal', 'lives,', 'so', 'the', 'therapy', 'has', 'societal', 'value', 'in', 'addition', 'to', 'patient', 'value.', 'The', 'health-care', 'system', 'value', 'was', 'based', 'on', 'the', 'cost-effectiveness', 'studies', 'we', 'conducted.', 'The', 'results', 'from', 'our', 'studies', 'found', 'that', 'pricing', 'the', 'therapy', 'between', '$600,000', 'and', '$750,000', 'would', 'have', 'been', 'cost-effective', 'to', 'the', 'health-care', 'system,', 'but', 'we', 'decided', 'instead', 'to', 'have', 'a', 'list', 'price', 'of', '$475,000.', 'Since', 'then,', 'the', 'National', 'Institute', 'for', 'Health', 'and', 'Care', 'Excellence', 'and', 'the', 'Institute', 'for', 'Clinical', 'and', 'Economic', 'Review', 'have', 'confirmed', 'the', 'cost-effectiveness', 'of', 'tisagenlecleucel.', 'It', 'was', 'important', 'for', 'Novartis', 'to', 'find', 'a', 'price', 'for', 'this', 'one-time', 'therapy', 'that', 'allows', 'patients', 'to', 'access', 'care', 'through', 'the', 'U.S.', 'health-care', 'system', 'and', 'that', 'also', 'takes', 'into', 'account', 'the', 'innovation', 'and', 'investment', 'to', 'develop', 'such', 'a', 'transformative', 'therapy.', 'We', 'have', 'implemented', 'and', 'support', 'programs', 'and', 'outcomes-based', 'agreements', 'to', 'further', 'facilitate', 'patient', 'access', 'to', 'this', 'therapy.', 'I', 'think', 'we', 'can', 'all', 'agree', 'that', 'health', 'insurance', 'is', 'already', 'quite', 'expensive', 'in', 'the', 'U.S.,', 'and', 'nobody', 'likes', 'to', 'see', 'premiums', 'increase,', 'she', 'added.', 'But', 'if', 'we', 'dont', 'want', 'premiums', 'to', 'keep', 'increasing,', 'it', 'is', 'necessary', 'to', 'evaluate', 'new', 'therapies', 'thoroughly', 'and', 'assess', 'the', 'benefit', 'they', 'bring', 'for', 'their', 'cost,', 'and', 'how', 'that', 'ratio', 'compares', 'to', 'that', 'of', 'other', 'health', 'services.', 'The', 'important', 'thing', 'is', 'to', 'first', 'determine', 'whether', 'the', 'patient', 'meets', 'criteria', 'for', 'the', 'FDA-approved', 'indication,', 'because', 'insurance', 'companies', 'carefully', 'look', 'at', 'that', 'to', 'determine', 'whether', \"they'll\", 'cover', 'someone', 'treated', 'with', 'CAR', 'T', 'cells.', 'That', 'has', 'been', 'a', 'challenge.', 'It', 'is', 'within', 'this', 'context', 'that', 'the', 'excitement', 'surrounding', 'CAR', 'T-cell', 'therapy', 'is', 'balanced', 'against', 'the', 'reality', 'of', 'another', 'case', 'of', 'false', 'hope.', 'Many', 'patients', 'might', 'feel', 'that', 'they', 'are', 'missing', 'out', 'on', 'a', 'new', 'wonder', 'drug,', 'a', 'feeling', 'that', 'might', 'be', 'further', 'exacerbated', 'by', 'international', 'differences', 'in', 'eligibility', 'criteria;', 'for', 'example,', 'the', 'threshold', 'of', 'minimally', 'residual', 'disease', 'at', 'which', 'a', 'child', 'is', 'eligible', 'for', 'CAR', 'T-cell', 'therapy', 'is', 'more', 'liberal', 'in', 'the', 'USA', 'than', 'in', 'the', 'UK.', 'But', 'these', 'differences', 'are', 'misleading', 'and', 'are', 'a', 'consequence', 'of', 'the', 'scant', 'clinical', 'evidence', 'available', 'currently,', 'and', 'the', 'subjective', 'nature', 'of', 'clinical', 'decision', 'making', 'for', 'these', 'specific', 'treatments.', 'Payers', 'should', 'factor', 'in', 'nondrug', 'costs', 'when', 'making', 'decisions', 'on', 'the', 'coverage', 'of', 'these', 'therapies', 'and', 'when', 'negotiating', 'prices', 'with', 'manufacturers.', 'For', 'the', 'health', 'care', 'systems', 'perspective,', 'the', 'key', 'point', 'is', 'that', 'health', 'care', 'resources', 'are', 'not', 'unlimited,', 'Hernandez', 'told', 'HemOnc', 'Today.', 'Money', 'needed', 'to', 'cover', 'new', 'highly', 'expensive', 'therapies', 'with', 'a', 'high', 'budget', 'impact,', 'such', 'as', 'CAR', 'T-cell', 'therapy,', 'needs', 'to', 'come', 'from', 'somewhere', '-', 'either', 'from', 'a', 'reallocation', 'of', 'funds', 'from', 'other', 'therapies', 'and', 'health', 'services', 'that', 'will', 'no', 'longer', 'be', 'covered', 'or', 'from', 'increased', 'premiums.', 'Programs', 'like', 'Novartiss', 'outcomes-based', 'pricing', 'for', 'tisagenlecleucel', 'may', 'help', 'curb', 'costs;', 'however,', 'the', 'impact', 'on', 'the', 'health', 'care', 'system', 'is', 'large,', 'Hernandez', 'said.', 'Dr.', 'June:', 'To', 'begin,', 'there', 'are', 'CD19', 'CAR', 'T', 'cells,', 'and', 'the', 'initial', 'response', 'rate', 'and', 'remission', 'durations', 'are', 'very', 'different', 'depending', 'on', 'the', 'type', 'of', 'cancer', 'the', 'patient', 'has.', 'The', 'first', 'patients', 'we', 'treated', 'with', 'CLL', 'in', '2010', 'are', 'still', 'in', 'remission.', 'We', 'have', 'the', 'most', 'durability', 'data', 'in', 'patients', 'with', 'CLL,', 'and', 'its', 'very', 'rare', 'to', 'relapse,', 'but', 'the', 'remission', 'rate', 'is', 'about', '50%', 'currently.', 'In', 'ALL,', 'the', 'remission', 'rate', 'in', 'multiple', 'studies', 'is', 'between', '80%', 'and', '90%.', 'In', 'one', 'of', 'our', 'trials,', 'there', 'was', 'a', '28%', 'relapse', 'rate', 'after', '1', 'year,', 'but', 'after', 'that,', 'it', 'is', 'very', 'rare', 'to', 'experience', 'relapse,', 'and', 'the', 'relapses', 'that', 'do', 'occur', 'are', 'usually', 'due', 'to', 'the', 'loss', 'of', 'the', 'CD19', 'part', 'of', 'the', 'molecule', 'on', 'the', 'leukemia', 'cells.', 'Thats', 'different', 'from', 'what', 'happens', 'in', 'lymphoma,', 'where', 'the', 'complete', 'response', 'rate', 'is', '40%,', 'and', 'its', 'rare', 'to', 'have', 'relapses', 'in', 'those', 'patients;', 'when', 'they', 'do', 'relapse,', 'it', 'is', 'not', 'usually', 'with', 'a', 'CD19', 'target', 'loss', 'like', 'in', 'ALL.', 'What', 'happens', 'after', 'patients', 'are', 'treated', 'depends', 'on', 'what', 'type', 'of', 'tumor', 'they', 'have.', 'There', 'is', 'not', 'a', 'one-size-fits-all', 'treatment.', 'When', 'patients', 'relapse', 'after', 'conventional', 'therapy,', 'they', 'may', 'go', 'on', 'to', 'other', 'experimental', 'therapies,', 'including', 'newer', 'generations', 'of', 'CAR', 'T', 'cells.', 'However,', 'when', 'patients', 'relapse', 'after', 'CAR', 'T-cell', 'therapy,', 'unfortunately,', 'they', 'usually', 'die', 'of', 'their', 'disease.', 'Dr.', 'Lonial:', 'Many', 'trials', 'are', 'now', 'allowing', 'patients', 'to', 'be', 're-treated,', 'so', 're-treating', 'may', 'make', 'sense.', 'What', 'weve', 'seen,', 'particularly', 'in', 'lymphoma', 'and', 'ALL,', 'is', 'the', 'idea', 'that', 'these', 'patients', 'were', 'treated', 'with', 'very', 'early-generation', 'CAR', 'T', 'cells;', 'if', 'these', 'were', 'the', 'only', 'data', 'we', 'had,', 'I', 'probably', 'would', 'not', 'be', 'as', 'excited', 'about', 'the', 'potential', 'for', 'this', 'therapy', 'to', 'revolutionize', 'the', 'field.', 'Youre', 'right.', 'Not', 'all', 'patients', 'respond', 'to', 'the', 'therapy,', 'and', 'the', 'durability', 'of', 'responses', 'can', 'be', 'limited;', 'some', 'of', 'that', 'may', 'be', 'due', 'to', 'patients', 'dealing', 'with', 'end-stage', 'disease,', 'when', 'its', 'much', 'more', 'difficult', 'to', 'achieve', 'a', 'long-term', 'response.', 'For', 'me,', 'what', 'shifted', 'the', 'potential', 'applicability', 'of', 'CAR', 'T', 'cells', 'in', 'cancer', 'were', 'the', 'data', 'we', 'saw', 'in', 'myeloma:', 'Even', 'in', 'refractory', 'disease,', '90%', 'of', 'patients', 'were', 'having', 'a', 'major', 'response', 'to', 'the', 'therapy.', 'And', 'in', 'the', 'follow-up', 'data', 'weve', 'seen,', 'many', 'of', 'those', 'patients,', 'over', 'two-thirds,', 'are', 'staying', 'in', 'remission', 'close', 'to', 'a', 'year', 'out.', 'These', 'results', 'suggested', 'to', 'me', 'there', 'may', 'be', 'modifications', 'and', 'evolution', 'in', 'the', 'way', 'we', 'think', 'about', 'making', 'CAR', 'T', 'cells', 'and', 'delivering', 'them', 'that', 'may', 'continue', 'to', 'improve', 'outcomes', 'for', 'patients.', 'We', 'are', 'launching', 'a', 'trial', 'at', 'our', 'center', 'combining', 'tisagenlecleucel', 'with', 'programmed', 'cell', 'death', 'protein', '1', '(PD-1)', 'inhibitors', 'in', 'patients', 'with', 'lymphoma', 'to', 'try', 'to', 'improve', 'the', 'longevity', 'of', 'the', 'cell', 'and', 'ultimately', 'the', 'long-term', 'antitumor', 'effects', 'of', 'the', 'therapy.', 'Its', 'just', 'a', 'matter', 'of', 'figuring', 'out,', 'in', 'a', 'deliberate', 'and', 'scientific', 'way,', 'what', 'are', 'the', 'best', 'treatment', 'combinations', 'and', 'who', 'are', 'the', 'patients', 'being', 'treated;', 'it', 'is', 'not', 'just', 'the', 'CAR', 'T-cell', 'product', 'we', 'have', 'to', 'look', 'at,', 'it', 'is', 'the', 'quality', 'of', 'the', 'T', 'cells', 'being', 'used', 'to', 'make', 'the', 'product', 'as', 'well.', 'What', 'we', 'can', 'do', 'to', 'the', 'host', 'to', 'augment', 'the', 'production', 'of', 'effective', 'T', 'cells', 'and', 'what', 'we', 'can', 'do', 'to', 'the', 'cells', 'once', 'they', 'have', 'been', 'extracted', 'to', 'augment', 'their', 'efficacy', 'and', 'long-term', 'benefit', 'are', 'being', 'investigated', 'now.', 'Dr.', 'Maloney:', 'In', 'my', 'experience,', 'it', 'is', 'seldom', 'effective', 'to', 're-treat', 'patients', 'with', 'this', 'therapy.', 'Occasionally,', 'the', 'same', 'patients', 'may', 'respond', 'to', 'the', 'same', 'CAR', 'T', 'cells,', 'but', 'in', 'many', 'cases,', 'the', 'reason', 'they', 'relapse', 'and', 'the', 'reason', 'the', 'therapy', 'may', 'be', 'ineffective', 'are', 'the', 'patients', 'immune', 'system', 'rejects', 'the', 'CAR', 'T', 'cells,', 'because', 'they', 'are', 'a', 'foreign', 'protein', 'on', 'the', 'surface', 'of', 'the', 'T', 'cells.', 'Its', 'important', 'to', 'note', 'the', 'three', 'CARs', 'likely', 'to', 'be', 'approved', 'in', 'lymphoma', 'in', 'the', 'near', 'future,', 'including', 'JCAR017,', 'all', 'use', 'the', 'same', 'murine', 'single-chain', 'Fv', 'antibody-that', 'means', 'if', 'a', 'patient', 'rejects', 'one', 'product,', 'she', 'or', 'he', 'is', 'unlikely', 'to', 'respond', 'to', 'the', 'other', 'two.', 'However,', 'a', 'patient', 'who', 'rejects', 'one', 'CAR', 'T', 'cell', 'may', 'respond', 'to', 'a', 'totally', 'different', 'CAR', 'T', 'cell.', 'For', 'example,', 'a', 'CAR', 'T', 'cell', 'against', 'a', 'different', 'target', 'would', 'be', 'an', 'option,', 'but', 'right', 'now', 'we', 'dont', 'have', 'very', 'many', 'other', 'targets', 'we', 'are', 'using', 'in', 'lymphoma.', 'One', 'option', 'is', 'CD22,', 'so', 'there', 'is', 'the', 'potential', 'of', 'using', 'a', 'totally', 'different', 'CAR', 'construct', 'with', 'a', 'different', 'antibody', 'single-chain', 'Fv,', 'but', 'we', 'have', 'to', 'study', 'this', 'further.', '...the', 'significant', 'toxicity', 'of', 'these', 'therapies,', 'the', 'complexity', 'of', 'its', 'administration,', 'and', 'the', 'logistics', 'surrounding', 'its', 'operation', 'might', 'hinder', 'the', 'commercial', 'uptake', 'and', 'market', 'success', 'of', 'CAR-T', 'therapy.', 'To', 'address', 'these', 'issues,', 'CAR-T', 'manufacturers', 'have', 'assured', 'the', 'FDA', 'that', 'treatment', 'will', 'be', 'limited', 'to', 'highly', 'specialized', 'centers', 'with', 'stem', 'cell', 'transplantation', 'capabilities.', 'Most', 'cancer', 'patients', 'are', 'seen', 'in', 'the', 'community', 'setting,10', 'thereby', 'community', 'oncologists', 'will', 'play', 'an', 'instrumental', 'role', 'in', 'patient', 'referral', 'and', 'likely', 'determine', 'the', 'initial', 'adoption', 'of', 'this', 'treatment.', 'Currently,', 'CAR', 'T-cell', 'therapy', 'is', 'only', 'considered', 'in', 'experimental', 'settings', 'after', 'exhausting', 'all', 'other', 'treatment', 'options', 'and', 'is', 'thus', 'used', 'as', 'a', 'treatment', 'of', 'last', 'resort']\n"
     ]
    }
   ],
   "source": [
    "content_cl_sp=[phrase.split() for phrase in text2]\n",
    "content_flat = [item for sublist in content_cl_sp for item in sublist]\n",
    "print(content_flat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package averaged_perceptron_tagger to\n",
      "[nltk_data]     C:\\nltk_data...\n",
      "[nltk_data]   Package averaged_perceptron_tagger is already up-to-\n",
      "[nltk_data]       date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[('Both', 'DT'),\n",
       " ('tisagenlecleucel', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('axicabtagene', 'JJ'),\n",
       " ('ciloleucel', 'NN'),\n",
       " ('carry', 'VBP'),\n",
       " ('a', 'DT'),\n",
       " ('black', 'JJ'),\n",
       " ('box', 'NN'),\n",
       " ('warning', 'VBG'),\n",
       " ('for', 'IN'),\n",
       " ('cytokine-release', 'JJ'),\n",
       " ('syndrome', 'NN'),\n",
       " ('(CRS)', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('for', 'IN'),\n",
       " ('neurologic', 'JJ'),\n",
       " ('events.', 'NN'),\n",
       " ('To', 'TO'),\n",
       " ('treat', 'VB'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell-induced', 'NNP'),\n",
       " ('severe', 'VBD'),\n",
       " ('or', 'CC'),\n",
       " ('life-threatening', 'JJ'),\n",
       " ('CRS,', 'NNP'),\n",
       " ('the', 'DT'),\n",
       " ('FDA', 'NNP'),\n",
       " ('expanded', 'VBD'),\n",
       " ('the', 'DT'),\n",
       " ('approval', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('tocilizumab', 'JJ'),\n",
       " ('(Actemra)', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('has', 'VBZ'),\n",
       " ('required', 'VBN'),\n",
       " ('that', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('be', 'VB'),\n",
       " ('performed', 'VBN'),\n",
       " ('only', 'RB'),\n",
       " ('in', 'IN'),\n",
       " ('cancer', 'NN'),\n",
       " ('centers', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('have', 'VBP'),\n",
       " ('completed', 'VBN'),\n",
       " ('training', 'NN'),\n",
       " ('in', 'IN'),\n",
       " ('Risk', 'NNP'),\n",
       " ('Evaluation', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('Mitigation', 'NNP'),\n",
       " ('Strategy', 'NNP'),\n",
       " ('to', 'TO'),\n",
       " ('support', 'VB'),\n",
       " ('its', 'PRP$'),\n",
       " ('safe', 'JJ'),\n",
       " ('use.', 'JJ'),\n",
       " ('Currently,', 'NNP'),\n",
       " ('about', 'IN'),\n",
       " ('40', 'CD'),\n",
       " ('cancer', 'NN'),\n",
       " ('centers', 'NNS'),\n",
       " ('are', 'VBP'),\n",
       " ('certified', 'VBN'),\n",
       " ('to', 'TO'),\n",
       " ('offer', 'VB'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('patients.', 'VB'),\n",
       " ('Weve', 'NNP'),\n",
       " ('learned', 'VBD'),\n",
       " ('how', 'WRB'),\n",
       " ('to', 'TO'),\n",
       " ('grade', 'VB'),\n",
       " ('(CRS),', 'NNP'),\n",
       " ('weve', 'NN'),\n",
       " ('learned', 'VBD'),\n",
       " ('how', 'WRB'),\n",
       " ('to', 'TO'),\n",
       " ('treat', 'VB'),\n",
       " ('it,', 'JJ'),\n",
       " ('Dr.', 'NNP'),\n",
       " ('Grupp', 'NNP'),\n",
       " ('said', 'VBD'),\n",
       " ('during', 'IN'),\n",
       " ('an', 'DT'),\n",
       " ('FDA', 'NNP'),\n",
       " ('advisory', 'JJ'),\n",
       " ('committee', 'NN'),\n",
       " ('meeting', 'NN'),\n",
       " ('on', 'IN'),\n",
       " ('Novartis', 'NNP'),\n",
       " ('CD19-targeted', 'NNP'),\n",
       " ('therapy.', 'NN'),\n",
       " ('And', 'CC'),\n",
       " ('IL-6', 'NNP'),\n",
       " ('blockade', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('really', 'RB'),\n",
       " ('the', 'DT'),\n",
       " ('key.', 'NN'),\n",
       " ('Other', 'JJ'),\n",
       " ('so-called', 'JJ'),\n",
       " ('neurotoxicities-such', 'JJ'),\n",
       " ('as', 'IN'),\n",
       " ('confusion', 'NN'),\n",
       " ('or', 'CC'),\n",
       " ('seizure-like', 'JJ'),\n",
       " ('activity-have', 'JJ'),\n",
       " ('been', 'VBN'),\n",
       " ('seen', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('most', 'JJS'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('trials.', 'NN'),\n",
       " ('But', 'CC'),\n",
       " ('in', 'IN'),\n",
       " ('nearly', 'RB'),\n",
       " ('all', 'DT'),\n",
       " ('patients', 'NNS'),\n",
       " ('the', 'DT'),\n",
       " ('problem', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('short', 'JJ'),\n",
       " ('lived', 'JJ'),\n",
       " ('and', 'CC'),\n",
       " ('reversible,', 'JJ'),\n",
       " ('Dr.', 'NNP'),\n",
       " ('Brentjens', 'NNP'),\n",
       " ('said.', 'NN'),\n",
       " ('There', 'EX'),\n",
       " ('was', 'VBD'),\n",
       " ('speculation', 'NN'),\n",
       " ('early', 'RB'),\n",
       " ('on', 'IN'),\n",
       " ('that', 'IN'),\n",
       " ('these', 'DT'),\n",
       " ('neurotoxicities', 'NNS'),\n",
       " ('might', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('related', 'VBN'),\n",
       " ('to', 'TO'),\n",
       " ('CRS.', 'NNP'),\n",
       " ('But', 'CC'),\n",
       " ('although', 'IN'),\n",
       " ('researchers', 'NNS'),\n",
       " ('are', 'VBP'),\n",
       " ('still', 'RB'),\n",
       " ('trying', 'VBG'),\n",
       " ('to', 'TO'),\n",
       " ('get', 'VB'),\n",
       " ('their', 'PRP$'),\n",
       " ('hands', 'NNS'),\n",
       " ('around', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('mechanisms,', 'NN'),\n",
       " ('he', 'PRP'),\n",
       " ('added,', 'VBD'),\n",
       " ('I', 'PRP'),\n",
       " ('think', 'VBP'),\n",
       " ('most', 'JJS'),\n",
       " ('investigators', 'NNS'),\n",
       " ('(in', 'VBP'),\n",
       " ('the', 'DT'),\n",
       " ('field)', 'NN'),\n",
       " ('would', 'MD'),\n",
       " ('agree', 'VB'),\n",
       " ('that', 'IN'),\n",
       " ('theyre', 'JJ'),\n",
       " ('distinct', 'NN'),\n",
       " ('from', 'IN'),\n",
       " ('CRS.', 'NNP'),\n",
       " ('Furthermore,', 'NNP'),\n",
       " ('toxicity', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('a', 'DT'),\n",
       " ('significant', 'JJ'),\n",
       " ('concern', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapies;', 'NN'),\n",
       " ('severe', 'JJ'),\n",
       " ('neurotoxicity', 'NN'),\n",
       " ('has', 'VBZ'),\n",
       " ('been', 'VBN'),\n",
       " ('observed,', 'VBN'),\n",
       " ('though', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('mortality', 'NN'),\n",
       " ('rate', 'NN'),\n",
       " ('for', 'IN'),\n",
       " ('these', 'DT'),\n",
       " ('adverse', 'JJ'),\n",
       " ('events', 'NNS'),\n",
       " ('remains', 'VBZ'),\n",
       " ('low,', 'JJ'),\n",
       " ('at', 'IN'),\n",
       " ('around', 'IN'),\n",
       " ('2%', 'CD'),\n",
       " ('to', 'TO'),\n",
       " ('3%', 'CD'),\n",
       " ('across', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('approximately', 'RB'),\n",
       " ('230', 'CD'),\n",
       " ('patients', 'NNS'),\n",
       " ('studied', 'VBN'),\n",
       " ('so', 'RB'),\n",
       " ('far,', 'JJ'),\n",
       " ('said', 'VBD'),\n",
       " ('Shah.', 'NNP'),\n",
       " ('Interestingly,', 'NNP'),\n",
       " ('ALL', 'NNP'),\n",
       " ('seems', 'VBZ'),\n",
       " ('to', 'TO'),\n",
       " ('have', 'VB'),\n",
       " ('a', 'DT'),\n",
       " ('higher', 'JJR'),\n",
       " ('rate', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('neurologic', 'JJ'),\n",
       " ('toxicity', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T', 'NNP'),\n",
       " ('than', 'IN'),\n",
       " ('other', 'JJ'),\n",
       " ('cancers', 'NNS'),\n",
       " ('do,', 'VBP'),\n",
       " ('an', 'DT'),\n",
       " ('observation', 'NN'),\n",
       " ('that', 'WDT'),\n",
       " ('suggests', 'VBZ'),\n",
       " ('that', 'IN'),\n",
       " ('there', 'EX'),\n",
       " ('are', 'VBP'),\n",
       " ('some', 'DT'),\n",
       " ('disease', 'NN'),\n",
       " ('features', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('linked', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('adverse', 'JJ'),\n",
       " ('events', 'NNS'),\n",
       " ('(AEs).', 'JJ'),\n",
       " ('Adults', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('ALL', 'DT'),\n",
       " ('appear', 'VBP'),\n",
       " ('to', 'TO'),\n",
       " ('have', 'VB'),\n",
       " ('even', 'RB'),\n",
       " ('more', 'JJR'),\n",
       " ('neurotoxicity', 'NN'),\n",
       " ('than', 'IN'),\n",
       " ('younger', 'JJR'),\n",
       " ('patients.3', 'NN'),\n",
       " ('I', 'PRP'),\n",
       " ('have', 'VBP'),\n",
       " ('no', 'DT'),\n",
       " ('explanation', 'NN'),\n",
       " ('for', 'IN'),\n",
       " ('this,', 'NN'),\n",
       " ('Shah', 'NNP'),\n",
       " ('said.', 'NN'),\n",
       " ('If', 'IN'),\n",
       " ('fever', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('hypotension', 'NN'),\n",
       " ('do', 'VBP'),\n",
       " ('not', 'RB'),\n",
       " ('resolve', 'VB'),\n",
       " ('with', 'IN'),\n",
       " ('tocilizumab,', 'JJ'),\n",
       " ('my', 'PRP$'),\n",
       " ('own', 'JJ'),\n",
       " ('personal', 'JJ'),\n",
       " ('bias', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('that', 'IN'),\n",
       " ('more', 'JJR'),\n",
       " ('tocilizumab', 'JJ'),\n",
       " ('wont', 'NN'),\n",
       " ('help,', 'NN'),\n",
       " ('said', 'VBD'),\n",
       " ('Shah,', 'NNP'),\n",
       " ('who', 'WP'),\n",
       " ('would', 'MD'),\n",
       " ('resort', 'VB'),\n",
       " ('to', 'TO'),\n",
       " ('steroids', 'VB'),\n",
       " ('in', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('case.', 'NN'),\n",
       " ('Theyre', 'NNP'),\n",
       " ('bad,', 'NN'),\n",
       " ('but', 'CC'),\n",
       " ('theyre', 'VBZ'),\n",
       " ('not', 'RB'),\n",
       " ('that', 'DT'),\n",
       " ('bad.', 'NN'),\n",
       " ('He', 'PRP'),\n",
       " ('urged', 'VBD'),\n",
       " ('clinicians', 'NNS'),\n",
       " ('not', 'RB'),\n",
       " ('to', 'TO'),\n",
       " ('be', 'VB'),\n",
       " ('afraid', 'VBN'),\n",
       " ('to', 'TO'),\n",
       " ('put', 'VB'),\n",
       " ('a', 'DT'),\n",
       " ('patient', 'NN'),\n",
       " ('on', 'IN'),\n",
       " ('steroids', 'NNS'),\n",
       " ('as', 'RB'),\n",
       " ('long', 'RB'),\n",
       " ('as', 'IN'),\n",
       " ('they', 'PRP'),\n",
       " ('are', 'VBP'),\n",
       " ('willing', 'JJ'),\n",
       " ('to', 'TO'),\n",
       " ('stop', 'VB'),\n",
       " ('the', 'DT'),\n",
       " ('course', 'NN'),\n",
       " ('once', 'RB'),\n",
       " ('CRS', 'NNP'),\n",
       " ('symptoms', 'NNS'),\n",
       " ('start', 'VBP'),\n",
       " ('to', 'TO'),\n",
       " ('improve.', 'VB'),\n",
       " ('Cerebral', 'NNP'),\n",
       " ('edema', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('another', 'DT'),\n",
       " ('challenging', 'VBG'),\n",
       " ('AE,', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('the', 'DT'),\n",
       " ('answer', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('nobody', 'JJ'),\n",
       " ('knows', 'NNS'),\n",
       " ('why', 'WRB'),\n",
       " ('cerebral', 'JJ'),\n",
       " ('edema', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('observed', 'VBN'),\n",
       " ('among', 'IN'),\n",
       " ('6', 'CD'),\n",
       " ('patients', 'NNS'),\n",
       " ('treated', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('Junos', 'NNP'),\n",
       " ('trial', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('its', 'PRP$'),\n",
       " ('proposed', 'VBN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy,', 'NN'),\n",
       " ('JCAR015,', 'NNP'),\n",
       " ('which', 'WDT'),\n",
       " ('resulted', 'VBD'),\n",
       " ('in', 'IN'),\n",
       " ('multiple', 'JJ'),\n",
       " ('deaths.', 'VBP'),\n",
       " ('The', 'DT'),\n",
       " ('mechanisms', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('AE', 'NNP'),\n",
       " ('remain', 'VBP'),\n",
       " ('elusive.', 'JJ'),\n",
       " ('We', 'PRP'),\n",
       " ('worry', 'VBP'),\n",
       " ('not', 'RB'),\n",
       " ('only', 'RB'),\n",
       " ('about', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('associated', 'JJ'),\n",
       " ('chemotherapy', 'JJ'),\n",
       " ('side', 'NN'),\n",
       " ('effects-nausea,', 'JJ'),\n",
       " ('vomiting,', 'JJ'),\n",
       " ('hair', 'NN'),\n",
       " ('loss-because', 'NN'),\n",
       " ('they', 'PRP'),\n",
       " ('do', 'VBP'),\n",
       " ('get', 'VB'),\n",
       " ('some', 'DT'),\n",
       " ('low-dose', 'JJ'),\n",
       " ('chemotherapy', 'NN'),\n",
       " ('prior', 'RB'),\n",
       " ('to', 'TO'),\n",
       " ('getting', 'VBG'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T', 'NNP'),\n",
       " ('cells,', 'NN'),\n",
       " ('but', 'CC'),\n",
       " ('the', 'DT'),\n",
       " ('unique', 'JJ'),\n",
       " ('side', 'NN'),\n",
       " ('effects', 'NNS'),\n",
       " ('we', 'PRP'),\n",
       " ('recognize', 'VBP'),\n",
       " ('with', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T', 'NNP'),\n",
       " ('cells', 'NNS'),\n",
       " ('include', 'VBP'),\n",
       " ('CRS', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('neurological', 'JJ'),\n",
       " ('toxicities.', 'NN'),\n",
       " ('The', 'DT'),\n",
       " ('CRS', 'NNP'),\n",
       " ('can', 'MD'),\n",
       " ('be,', 'VB'),\n",
       " ('in', 'IN'),\n",
       " ('some', 'DT'),\n",
       " ('mild', 'JJ'),\n",
       " ('cases,', 'NNS'),\n",
       " ('characterized', 'VBN'),\n",
       " ('by', 'IN'),\n",
       " ('fevers,', 'JJ'),\n",
       " ('chills,', 'NNS'),\n",
       " ('slightly', 'RB'),\n",
       " ('low', 'JJ'),\n",
       " ('blood', 'NN'),\n",
       " ('pressure', 'NN'),\n",
       " ('that', 'WDT'),\n",
       " ('responds', 'VBZ'),\n",
       " ('to', 'TO'),\n",
       " ('intravenous', 'JJ'),\n",
       " ('fluids', 'NNS'),\n",
       " ('to,', 'NN'),\n",
       " ('in', 'IN'),\n",
       " ('extreme', 'JJ'),\n",
       " ('cases,', 'NN'),\n",
       " ('fevers', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('very', 'RB'),\n",
       " ('high,', 'JJ'),\n",
       " ('and', 'CC'),\n",
       " ('blood', 'NN'),\n",
       " ('pressure', 'NN'),\n",
       " ('that', 'WDT'),\n",
       " ('drops', 'VBZ'),\n",
       " ('low', 'JJ'),\n",
       " ('enough', 'RB'),\n",
       " ('to', 'TO'),\n",
       " ('require', 'VB'),\n",
       " ('medication.', 'NN'),\n",
       " ('In', 'IN'),\n",
       " ('terms', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('neurological', 'JJ'),\n",
       " ('toxicity,', 'NN'),\n",
       " ('some', 'DT'),\n",
       " ('patients', 'NNS'),\n",
       " (\"don't\", 'VBP'),\n",
       " ('have', 'VBP'),\n",
       " ('any.', 'VBN'),\n",
       " ('Others', 'NNS'),\n",
       " ('might', 'MD'),\n",
       " ('have', 'VB'),\n",
       " ('mild', 'VBN'),\n",
       " ('confusion.', 'NNS'),\n",
       " ('In', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('severe', 'JJ'),\n",
       " ('extreme,', 'NN'),\n",
       " ('patients', 'NNS'),\n",
       " ('can', 'MD'),\n",
       " ('become', 'VB'),\n",
       " ('comatose', 'JJ'),\n",
       " ('or', 'CC'),\n",
       " ('have', 'VBP'),\n",
       " ('seizures', 'VBN'),\n",
       " ('as', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('result', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('neurotoxicity.', 'JJ'),\n",
       " ('Thus', 'NNP'),\n",
       " ('far,', 'VBD'),\n",
       " ('the', 'DT'),\n",
       " ('companies', 'NNS'),\n",
       " ('have', 'VBP'),\n",
       " ('been', 'VBN'),\n",
       " ('very', 'RB'),\n",
       " ('careful', 'JJ'),\n",
       " ('in', 'IN'),\n",
       " ('terms', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('having', 'VBG'),\n",
       " ('sites', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('have', 'VBP'),\n",
       " ('experience', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('adequate', 'JJ'),\n",
       " ('training', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('treat', 'VB'),\n",
       " ('patients.', 'JJ'),\n",
       " (\"They're\", 'NNP'),\n",
       " ('limiting', 'VBG'),\n",
       " ('the', 'DT'),\n",
       " ('first', 'JJ'),\n",
       " ('roll-out', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('sites', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('able', 'JJ'),\n",
       " ('to', 'TO'),\n",
       " ('manage', 'VB'),\n",
       " ('these', 'DT'),\n",
       " ('toxicities,', 'NNS'),\n",
       " ('because', 'IN'),\n",
       " ('it', 'PRP'),\n",
       " ('is', 'VBZ'),\n",
       " ('a', 'DT'),\n",
       " ('multimodality', 'NN'),\n",
       " ('management.', 'NN'),\n",
       " ('Questions', 'NNS'),\n",
       " ('about', 'IN'),\n",
       " ('toxicity', 'NN'),\n",
       " ('centered', 'VBN'),\n",
       " ('on', 'IN'),\n",
       " ('how', 'WRB'),\n",
       " ('optimal', 'JJ'),\n",
       " ('management', 'NN'),\n",
       " ('should', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('delivered.', 'VBN'),\n",
       " ('Over', 'IN'),\n",
       " ('60%', 'CD'),\n",
       " ('suggested', 'VBD'),\n",
       " ('that', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('should', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('monitored', 'VBN'),\n",
       " ('for', 'IN'),\n",
       " ('1', 'CD'),\n",
       " ('to', 'TO'),\n",
       " ('2', 'CD'),\n",
       " ('weeks', 'NNS'),\n",
       " ('after', 'IN'),\n",
       " ('administration.', 'JJ'),\n",
       " ('Notably,', 'NNP'),\n",
       " ('one-third', 'NN'),\n",
       " ('stated', 'VBD'),\n",
       " ('that', 'IN'),\n",
       " ('toxicity', 'NN'),\n",
       " ('might', 'MD'),\n",
       " ('hinder', 'VB'),\n",
       " ('their', 'PRP$'),\n",
       " ('prescribing', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('therapy.', 'NN'),\n",
       " ('Additionally,', 'NNP'),\n",
       " ('the', 'DT'),\n",
       " ('side-effects', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('immunotherapy', 'NN'),\n",
       " ('can', 'MD'),\n",
       " ('overshadow', 'VB'),\n",
       " ('clinical', 'JJ'),\n",
       " ('benefits,', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('proving', 'VBG'),\n",
       " ('to', 'TO'),\n",
       " ('be', 'VB'),\n",
       " ('particularly', 'RB'),\n",
       " ('challenging:', 'NN'),\n",
       " ('for', 'IN'),\n",
       " ('example,', 'JJ'),\n",
       " ('95%', 'CD'),\n",
       " ('of', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('treated', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('axicabtagene', 'JJ'),\n",
       " ('ciloleucel', 'NN'),\n",
       " ('had', 'VBD'),\n",
       " ('adverse', 'JJ'),\n",
       " ('events', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('grade', 'NN'),\n",
       " ('3', 'CD'),\n",
       " ('or', 'CC'),\n",
       " ('worse,', 'VB'),\n",
       " ('including', 'VBG'),\n",
       " ('haematological', 'JJ'),\n",
       " ('and', 'CC'),\n",
       " ('neurological', 'JJ'),\n",
       " ('toxicities.', 'NN'),\n",
       " ('When', 'WRB'),\n",
       " ('asked', 'VBD'),\n",
       " ('about', 'IN'),\n",
       " ('published', 'VBN'),\n",
       " ('information', 'NN'),\n",
       " ('from', 'IN'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trials,', 'NN'),\n",
       " ('almost', 'RB'),\n",
       " ('half', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('participants', 'NNS'),\n",
       " ('were', 'VBD'),\n",
       " ('not', 'RB'),\n",
       " ('familiar', 'JJ'),\n",
       " ('with', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('efficacy', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('toxicity', 'NN'),\n",
       " ('data', 'NNS'),\n",
       " ('on', 'IN'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('therapy.', 'NN'),\n",
       " ('Despite', 'IN'),\n",
       " ('most', 'JJS'),\n",
       " ('respondents', 'NNS'),\n",
       " ('labeling', 'VBG'),\n",
       " ('CAR-T', 'JJ'),\n",
       " ('therapy', 'NN'),\n",
       " ('as', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('potentially', 'RB'),\n",
       " ('game-changing', 'JJ'),\n",
       " ('approach,', 'NN'),\n",
       " ('only', 'RB'),\n",
       " ('20%', 'CD'),\n",
       " ('had', 'VBD'),\n",
       " ('ever', 'RB'),\n",
       " ('referred', 'VBN'),\n",
       " ('a', 'DT'),\n",
       " ('patient', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('a', 'DT'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trial', 'NN'),\n",
       " ('Our', 'PRP$'),\n",
       " ('study', 'NN'),\n",
       " ('highlights', 'NNS'),\n",
       " ('several', 'JJ'),\n",
       " ('findings', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('critical', 'JJ'),\n",
       " ('to', 'TO'),\n",
       " ('all', 'DT'),\n",
       " ('stakeholders.', 'NN'),\n",
       " ('First', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('foremost,', 'JJ'),\n",
       " ('lack', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('familiarity', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('published', 'VBN'),\n",
       " ('data', 'NNS'),\n",
       " ('might', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('predictable', 'JJ'),\n",
       " ('since', 'IN'),\n",
       " ('studies', 'NNS'),\n",
       " ('were', 'VBD'),\n",
       " ('conducted', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('refractory', 'NN'),\n",
       " ('diseases', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('commonly', 'RB'),\n",
       " ('treated', 'VBN'),\n",
       " ('at', 'IN'),\n",
       " ('academic', 'JJ'),\n",
       " ('sites.', 'NN'),\n",
       " ('Overcoming', 'VBG'),\n",
       " ('this', 'DT'),\n",
       " ('educational', 'JJ'),\n",
       " ('barrier', 'NN'),\n",
       " ('can', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('achieved', 'VBN'),\n",
       " ('through', 'IN'),\n",
       " ('data', 'NNS'),\n",
       " ('dissemination,', 'NNS'),\n",
       " ('webinars,', 'VBP'),\n",
       " ('regional', 'JJ'),\n",
       " ('symposia,', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('other', 'JJ'),\n",
       " ('venues.', 'NN'),\n",
       " ('When', 'WRB'),\n",
       " ('queried', 'VBN'),\n",
       " ('on', 'IN'),\n",
       " ('how', 'WRB'),\n",
       " ('their', 'PRP$'),\n",
       " ('prescribing', 'NN'),\n",
       " ('habits', 'NNS'),\n",
       " ('might', 'MD'),\n",
       " ('evolve', 'VB'),\n",
       " ('should', 'MD'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('therapies', 'NNS'),\n",
       " ('become', 'VBP'),\n",
       " ('FDA', 'NNP'),\n",
       " ('approved', 'VBD'),\n",
       " ('for', 'IN'),\n",
       " ('indications', 'NNS'),\n",
       " ('studied', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('ongoing', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('completed', 'VBD'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trials;', 'NN'),\n",
       " ('only', 'RB'),\n",
       " ('22%', 'CD'),\n",
       " ('suggested', 'VBD'),\n",
       " ('they', 'PRP'),\n",
       " ('are', 'VBP'),\n",
       " ('unlikely', 'JJ'),\n",
       " ('to', 'TO'),\n",
       " ('prescribe', 'VB'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('therapy.', 'JJ'),\n",
       " ('Lastly,', 'NNP'),\n",
       " ('we', 'PRP'),\n",
       " ('inquired', 'VBD'),\n",
       " ('about', 'IN'),\n",
       " ('barriers', 'NNS'),\n",
       " ('to', 'TO'),\n",
       " ('successful', 'JJ'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('implementation;', 'NN'),\n",
       " ('the', 'DT'),\n",
       " ('logistics', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('administration', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('the', 'DT'),\n",
       " ('most', 'RBS'),\n",
       " ('common', 'JJ'),\n",
       " ('barrier,', 'NN'),\n",
       " ('followed', 'VBN'),\n",
       " ('by', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('known', 'VBN'),\n",
       " ('and', 'CC'),\n",
       " ('perceived', 'VBN'),\n",
       " ('toxicities', 'NNS'),\n",
       " ('While', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('majority', 'NN'),\n",
       " ('believed', 'VBD'),\n",
       " ('that', 'DT'),\n",
       " ('medical', 'JJ'),\n",
       " ('oncologists', 'NNS'),\n",
       " ('should', 'MD'),\n",
       " ('oversee', 'VB'),\n",
       " ('the', 'DT'),\n",
       " ('management', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('CAR-T-treated', 'NNP'),\n",
       " ('patients,', 'NN'),\n",
       " ('22%', 'CD'),\n",
       " ('believed', 'VBD'),\n",
       " ('that', 'IN'),\n",
       " ('engaging', 'VBG'),\n",
       " ('critical', 'JJ'),\n",
       " ('care', 'NN'),\n",
       " ('physicians', 'NNS'),\n",
       " ('will', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('essential', 'JJ'),\n",
       " ('for', 'IN'),\n",
       " ('optimal', 'JJ'),\n",
       " ('care', 'NN'),\n",
       " ('We', 'PRP'),\n",
       " ('have', 'VBP'),\n",
       " ('reported', 'VBN'),\n",
       " ('on', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('very', 'RB'),\n",
       " ('high', 'JJ'),\n",
       " ('response', 'NN'),\n",
       " ('rates', 'NNS'),\n",
       " ('and', 'CC'),\n",
       " ('durable', 'JJ'),\n",
       " ('remission', 'NN'),\n",
       " ('rates', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('ALL.', 'NNP'),\n",
       " ('We', 'PRP'),\n",
       " ('have', 'VBP'),\n",
       " ('treated', 'VBN'),\n",
       " ('more', 'JJR'),\n",
       " ('than', 'IN'),\n",
       " ('300', 'CD'),\n",
       " ('patients', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('tisagenlecleucel', 'NN'),\n",
       " ('in', 'IN'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trials,', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('a', 'DT'),\n",
       " ('lot', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('that', 'DT'),\n",
       " ('information', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('used', 'VBN'),\n",
       " ('for', 'IN'),\n",
       " ('FDA', 'NNP'),\n",
       " ('approval', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('therapy.', 'NN'),\n",
       " ('Dr.', 'NNP'),\n",
       " ('Lonial:', 'NNP'),\n",
       " ('In', 'IN'),\n",
       " ('my', 'PRP$'),\n",
       " ('experience', 'NN'),\n",
       " ('treating', 'VBG'),\n",
       " ('patients', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('multiple', 'JJ'),\n",
       " ('myeloma,', 'VBP'),\n",
       " ('the', 'DT'),\n",
       " ('benefit', 'NN'),\n",
       " ('from', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('therapy', 'NN'),\n",
       " ('has', 'VBZ'),\n",
       " ('been', 'VBN'),\n",
       " ('quite', 'RB'),\n",
       " ('striking.', 'JJ'),\n",
       " ('In', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('small', 'JJ'),\n",
       " ('clinical', 'JJ'),\n",
       " ('study', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('second-generation', 'NN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('construct', 'NN'),\n",
       " ('targeting', 'VBG'),\n",
       " ('the', 'DT'),\n",
       " ('B-cell', 'NNP'),\n",
       " ('maturation', 'NN'),\n",
       " ('antigen', 'NN'),\n",
       " ('(BCMA)', 'NN'),\n",
       " ('in', 'IN'),\n",
       " ('multiple', 'JJ'),\n",
       " ('myeloma,', 'VBP'),\n",
       " ('the', 'DT'),\n",
       " ('overall', 'JJ'),\n",
       " ('response', 'NN'),\n",
       " ('rates', 'NNS'),\n",
       " ('looked', 'VBD'),\n",
       " ('even', 'RB'),\n",
       " ('better', 'JJR'),\n",
       " ('than', 'IN'),\n",
       " ('what', 'WP'),\n",
       " ('weve', 'VBP'),\n",
       " ('seen', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('CD19', 'NNP'),\n",
       " ('in', 'IN'),\n",
       " ('lymphoma', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('ALL.6', 'NNP'),\n",
       " ('Now,', 'NNP'),\n",
       " ('these', 'DT'),\n",
       " ('are', 'VBP'),\n",
       " ('very,', 'JJ'),\n",
       " ('very', 'RB'),\n",
       " ('early', 'JJ'),\n",
       " ('days,', 'NN'),\n",
       " ('but', 'CC'),\n",
       " ('I', 'PRP'),\n",
       " ('think', 'VBP'),\n",
       " ('the', 'DT'),\n",
       " ('responses', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('durability', 'NN'),\n",
       " ('are', 'VBP'),\n",
       " ('going', 'VBG'),\n",
       " ('to', 'TO'),\n",
       " ('be', 'VB'),\n",
       " ('quite', 'RB'),\n",
       " ('impressive.', 'JJ'),\n",
       " ('Dr.', 'NNP'),\n",
       " ('Maloney:', 'NNP'),\n",
       " ('We', 'PRP'),\n",
       " ('have', 'VBP'),\n",
       " ('also', 'RB'),\n",
       " ('published', 'VBN'),\n",
       " ('extensively', 'RB'),\n",
       " ('on', 'IN'),\n",
       " ('our', 'PRP$'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trials', 'NNS'),\n",
       " ('data', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('chronic', 'JJ'),\n",
       " ('lymphocytic', 'JJ'),\n",
       " ('leukemia', 'NN'),\n",
       " ('(CLL),', 'NNP'),\n",
       " ('lymphoma,', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('ALL,', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('there', 'EX'),\n",
       " ('is', 'VBZ'),\n",
       " ('clearly', 'RB'),\n",
       " ('a', 'DT'),\n",
       " ('high', 'JJ'),\n",
       " ('initial', 'JJ'),\n",
       " ('response', 'NN'),\n",
       " ('rate', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy.', 'NN'),\n",
       " ('We', 'PRP'),\n",
       " ('are', 'VBP'),\n",
       " ('seeing', 'VBG'),\n",
       " ('remission', 'NN'),\n",
       " ('rates', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('whom', 'WP'),\n",
       " ('we', 'PRP'),\n",
       " ('did', 'VBD'),\n",
       " ('not', 'RB'),\n",
       " ('see', 'VB'),\n",
       " ('any', 'DT'),\n",
       " ('type', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('remission', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('conventional', 'JJ'),\n",
       " ('therapies.', 'JJ'),\n",
       " ('Some', 'DT'),\n",
       " ('patients', 'NNS'),\n",
       " ('relapse,', 'JJ'),\n",
       " ('and', 'CC'),\n",
       " ('we', 'PRP'),\n",
       " ('dont', 'VBP'),\n",
       " ('know', 'JJ'),\n",
       " ('whether', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('are', 'VBP'),\n",
       " ('cured', 'VBN'),\n",
       " ('yet,', 'RB'),\n",
       " ('and', 'CC'),\n",
       " ('there', 'EX'),\n",
       " ('can', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('serious', 'JJ'),\n",
       " ('toxicities', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('therapy.', 'NN'),\n",
       " ('Patients', 'NNPS'),\n",
       " ('undergoing', 'JJ'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ...]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# https://www.nltk.org/book/ch05.html\n",
    "nltk.download('averaged_perceptron_tagger')\n",
    "nltk.pos_tag(content_flat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "text3 = word_tokenize(text2[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Both',\n",
       " 'tisagenlecleucel',\n",
       " 'and',\n",
       " 'axicabtagene',\n",
       " 'ciloleucel',\n",
       " 'carry',\n",
       " 'a',\n",
       " 'black',\n",
       " 'box',\n",
       " 'warning',\n",
       " 'for',\n",
       " 'cytokine-release',\n",
       " 'syndrome',\n",
       " '(',\n",
       " 'CRS',\n",
       " ')',\n",
       " 'and',\n",
       " 'for',\n",
       " 'neurologic',\n",
       " 'events']"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text3[:20]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'!\"#$%&\\'()*+,-./:;<=>?@[\\\\]^_`{|}~'"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "string.punctuation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "token_list=[]\n",
    "for comment in text2:\n",
    "    tokenized_part = word_tokenize(comment)\n",
    "    token_list.append(tokenized_part)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['Both', 'tisagenlecleucel', 'and', 'axicabtagene', 'ciloleucel', 'carry', 'a', 'black', 'box', 'warning', 'for', 'cytokine-release', 'syndrome', '(', 'CRS', ')', 'and', 'for', 'neurologic', 'events', '.', 'To', 'treat', 'CAR', 'T-cell-induced', 'severe', 'or', 'life-threatening', 'CRS', ',', 'the', 'FDA', 'expanded', 'the', 'approval', 'of', 'tocilizumab', '(', 'Actemra', ')', 'and', 'has', 'required', 'that', 'CAR', 'T-cell', 'therapy', 'be', 'performed', 'only', 'in', 'cancer', 'centers', 'that', 'have', 'completed', 'training', 'in', 'Risk', 'Evaluation', 'and', 'Mitigation', 'Strategy', 'to', 'support', 'its', 'safe', 'use', '.', 'Currently', ',', 'about', '40', 'cancer', 'centers', 'are', 'certified', 'to', 'offer', 'CAR', 'T-cell', 'therapy', 'to', 'patients', '.'], ['Weve', 'learned', 'how', 'to', 'grade', '(', 'CRS', ')', ',', 'weve', 'learned', 'how', 'to', 'treat', 'it', ',', 'Dr.', 'Grupp', 'said', 'during', 'an', 'FDA', 'advisory', 'committee', 'meeting', 'on', 'Novartis', 'CD19-targeted', 'therapy', '.', 'And', 'IL-6', 'blockade', 'was', 'really', 'the', 'key', '.'], ['Other', 'so-called', 'neurotoxicities-such', 'as', 'confusion', 'or', 'seizure-like', 'activity-have', 'been', 'seen', 'in', 'most', 'CAR', 'T-cell', 'therapy', 'trials', '.', 'But', 'in', 'nearly', 'all', 'patients', 'the', 'problem', 'is', 'short', 'lived', 'and', 'reversible', ',', 'Dr.', 'Brentjens', 'said', '.'], ['There', 'was', 'speculation', 'early', 'on', 'that', 'these', 'neurotoxicities', 'might', 'be', 'related', 'to', 'CRS', '.', 'But', 'although', 'researchers', 'are', 'still', 'trying', 'to', 'get', 'their', 'hands', 'around', 'the', 'mechanisms', ',', 'he', 'added', ',', 'I', 'think', 'most', 'investigators', '(', 'in', 'the', 'field', ')', 'would', 'agree', 'that', 'theyre', 'distinct', 'from', 'CRS', '.'], ['Furthermore', ',', 'toxicity', 'is', 'a', 'significant', 'concern', 'with', 'CAR', 'T-cell', 'therapies', ';', 'severe', 'neurotoxicity', 'has', 'been', 'observed', ',', 'though', 'the', 'mortality', 'rate', 'for', 'these', 'adverse', 'events', 'remains', 'low', ',', 'at', 'around', '2', '%', 'to', '3', '%', 'across', 'the', 'approximately', '230', 'patients', 'studied', 'so', 'far', ',', 'said', 'Shah', '.', 'Interestingly', ',', 'ALL', 'seems', 'to', 'have', 'a', 'higher', 'rate', 'of', 'neurologic', 'toxicity', 'with', 'CAR', 'T', 'than', 'other', 'cancers', 'do', ',', 'an', 'observation', 'that', 'suggests', 'that', 'there', 'are', 'some', 'disease', 'features', 'that', 'are', 'linked', 'with', 'adverse', 'events', '(', 'AEs', ')', '.', 'Adults', 'with', 'ALL', 'appear', 'to', 'have', 'even', 'more', 'neurotoxicity', 'than', 'younger', 'patients.3', 'I', 'have', 'no', 'explanation', 'for', 'this', ',', 'Shah', 'said', '.']]\n"
     ]
    }
   ],
   "source": [
    "print(token_list[:5])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "content_flat = [item for sublist in token_list for item in sublist]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Both', 'tisagenlecleucel', 'and', 'axicabtagene', 'ciloleucel']"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "content_flat[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Both',\n",
       " 'tisagenlecleucel',\n",
       " 'and',\n",
       " 'axicabtagene',\n",
       " 'ciloleucel',\n",
       " 'carry',\n",
       " 'a',\n",
       " 'black',\n",
       " 'box',\n",
       " 'warning',\n",
       " 'for',\n",
       " 'cytokine-release',\n",
       " 'syndrome',\n",
       " 'CRS',\n",
       " 'and',\n",
       " 'for',\n",
       " 'neurologic',\n",
       " 'events',\n",
       " 'To',\n",
       " 'treat']"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "content_noPunc = [item for item in content_flat if item not in string.punctuation]\n",
    "content_noPunc[:20]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('Both', 'DT'),\n",
       " ('tisagenlecleucel', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('axicabtagene', 'JJ'),\n",
       " ('ciloleucel', 'NN'),\n",
       " ('carry', 'VBP'),\n",
       " ('a', 'DT'),\n",
       " ('black', 'JJ'),\n",
       " ('box', 'NN'),\n",
       " ('warning', 'VBG'),\n",
       " ('for', 'IN'),\n",
       " ('cytokine-release', 'JJ'),\n",
       " ('syndrome', 'NN'),\n",
       " ('CRS', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('for', 'IN'),\n",
       " ('neurologic', 'JJ'),\n",
       " ('events', 'NNS'),\n",
       " ('To', 'TO'),\n",
       " ('treat', 'VB'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell-induced', 'NNP'),\n",
       " ('severe', 'VBD'),\n",
       " ('or', 'CC'),\n",
       " ('life-threatening', 'JJ'),\n",
       " ('CRS', 'NNP'),\n",
       " ('the', 'DT'),\n",
       " ('FDA', 'NNP'),\n",
       " ('expanded', 'VBD'),\n",
       " ('the', 'DT'),\n",
       " ('approval', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('tocilizumab', 'JJ'),\n",
       " ('Actemra', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('has', 'VBZ'),\n",
       " ('required', 'VBN'),\n",
       " ('that', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('be', 'VB'),\n",
       " ('performed', 'VBN'),\n",
       " ('only', 'RB'),\n",
       " ('in', 'IN'),\n",
       " ('cancer', 'NN'),\n",
       " ('centers', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('have', 'VBP'),\n",
       " ('completed', 'VBN'),\n",
       " ('training', 'NN'),\n",
       " ('in', 'IN'),\n",
       " ('Risk', 'NNP'),\n",
       " ('Evaluation', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('Mitigation', 'NNP'),\n",
       " ('Strategy', 'NNP'),\n",
       " ('to', 'TO'),\n",
       " ('support', 'VB'),\n",
       " ('its', 'PRP$'),\n",
       " ('safe', 'JJ'),\n",
       " ('use', 'NN'),\n",
       " ('Currently', 'NNP'),\n",
       " ('about', 'IN'),\n",
       " ('40', 'CD'),\n",
       " ('cancer', 'NN'),\n",
       " ('centers', 'NNS'),\n",
       " ('are', 'VBP'),\n",
       " ('certified', 'VBN'),\n",
       " ('to', 'TO'),\n",
       " ('offer', 'VB'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('patients', 'NNS'),\n",
       " ('Weve', 'NNP'),\n",
       " ('learned', 'VBD'),\n",
       " ('how', 'WRB'),\n",
       " ('to', 'TO'),\n",
       " ('grade', 'VB'),\n",
       " ('CRS', 'NNP'),\n",
       " ('weve', 'NN'),\n",
       " ('learned', 'VBD'),\n",
       " ('how', 'WRB'),\n",
       " ('to', 'TO'),\n",
       " ('treat', 'VB'),\n",
       " ('it', 'PRP'),\n",
       " ('Dr.', 'NNP'),\n",
       " ('Grupp', 'NNP'),\n",
       " ('said', 'VBD'),\n",
       " ('during', 'IN'),\n",
       " ('an', 'DT'),\n",
       " ('FDA', 'NNP'),\n",
       " ('advisory', 'JJ'),\n",
       " ('committee', 'NN'),\n",
       " ('meeting', 'NN'),\n",
       " ('on', 'IN'),\n",
       " ('Novartis', 'NNP'),\n",
       " ('CD19-targeted', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('And', 'CC'),\n",
       " ('IL-6', 'NNP'),\n",
       " ('blockade', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('really', 'RB'),\n",
       " ('the', 'DT'),\n",
       " ('key', 'NN'),\n",
       " ('Other', 'JJ'),\n",
       " ('so-called', 'JJ'),\n",
       " ('neurotoxicities-such', 'JJ'),\n",
       " ('as', 'IN'),\n",
       " ('confusion', 'NN'),\n",
       " ('or', 'CC'),\n",
       " ('seizure-like', 'JJ'),\n",
       " ('activity-have', 'JJ'),\n",
       " ('been', 'VBN'),\n",
       " ('seen', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('most', 'JJS'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('trials', 'NNS'),\n",
       " ('But', 'CC'),\n",
       " ('in', 'IN'),\n",
       " ('nearly', 'RB'),\n",
       " ('all', 'DT'),\n",
       " ('patients', 'NNS'),\n",
       " ('the', 'DT'),\n",
       " ('problem', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('short', 'JJ'),\n",
       " ('lived', 'JJ'),\n",
       " ('and', 'CC'),\n",
       " ('reversible', 'JJ'),\n",
       " ('Dr.', 'NNP'),\n",
       " ('Brentjens', 'NNP'),\n",
       " ('said', 'VBD'),\n",
       " ('There', 'EX'),\n",
       " ('was', 'VBD'),\n",
       " ('speculation', 'NN'),\n",
       " ('early', 'RB'),\n",
       " ('on', 'IN'),\n",
       " ('that', 'IN'),\n",
       " ('these', 'DT'),\n",
       " ('neurotoxicities', 'NNS'),\n",
       " ('might', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('related', 'VBN'),\n",
       " ('to', 'TO'),\n",
       " ('CRS', 'NNP'),\n",
       " ('But', 'CC'),\n",
       " ('although', 'IN'),\n",
       " ('researchers', 'NNS'),\n",
       " ('are', 'VBP'),\n",
       " ('still', 'RB'),\n",
       " ('trying', 'VBG'),\n",
       " ('to', 'TO'),\n",
       " ('get', 'VB'),\n",
       " ('their', 'PRP$'),\n",
       " ('hands', 'NNS'),\n",
       " ('around', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('mechanisms', 'NN'),\n",
       " ('he', 'PRP'),\n",
       " ('added', 'VBD'),\n",
       " ('I', 'PRP'),\n",
       " ('think', 'VBP'),\n",
       " ('most', 'JJS'),\n",
       " ('investigators', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('field', 'NN'),\n",
       " ('would', 'MD'),\n",
       " ('agree', 'VB'),\n",
       " ('that', 'IN'),\n",
       " ('theyre', 'JJ'),\n",
       " ('distinct', 'NN'),\n",
       " ('from', 'IN'),\n",
       " ('CRS', 'NNP'),\n",
       " ('Furthermore', 'NNP'),\n",
       " ('toxicity', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('a', 'DT'),\n",
       " ('significant', 'JJ'),\n",
       " ('concern', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapies', 'NNS'),\n",
       " ('severe', 'JJ'),\n",
       " ('neurotoxicity', 'NN'),\n",
       " ('has', 'VBZ'),\n",
       " ('been', 'VBN'),\n",
       " ('observed', 'VBN'),\n",
       " ('though', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('mortality', 'NN'),\n",
       " ('rate', 'NN'),\n",
       " ('for', 'IN'),\n",
       " ('these', 'DT'),\n",
       " ('adverse', 'JJ'),\n",
       " ('events', 'NNS'),\n",
       " ('remains', 'VBZ'),\n",
       " ('low', 'JJ'),\n",
       " ('at', 'IN'),\n",
       " ('around', 'RB'),\n",
       " ('2', 'CD'),\n",
       " ('to', 'TO'),\n",
       " ('3', 'CD'),\n",
       " ('across', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('approximately', 'RB'),\n",
       " ('230', 'CD'),\n",
       " ('patients', 'NNS'),\n",
       " ('studied', 'VBN'),\n",
       " ('so', 'RB'),\n",
       " ('far', 'RB'),\n",
       " ('said', 'VBD'),\n",
       " ('Shah', 'NNP'),\n",
       " ('Interestingly', 'NNP'),\n",
       " ('ALL', 'NNP'),\n",
       " ('seems', 'VBZ'),\n",
       " ('to', 'TO'),\n",
       " ('have', 'VB'),\n",
       " ('a', 'DT'),\n",
       " ('higher', 'JJR'),\n",
       " ('rate', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('neurologic', 'JJ'),\n",
       " ('toxicity', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T', 'NNP'),\n",
       " ('than', 'IN'),\n",
       " ('other', 'JJ'),\n",
       " ('cancers', 'NNS'),\n",
       " ('do', 'VBP'),\n",
       " ('an', 'DT'),\n",
       " ('observation', 'NN'),\n",
       " ('that', 'WDT'),\n",
       " ('suggests', 'VBZ'),\n",
       " ('that', 'IN'),\n",
       " ('there', 'EX'),\n",
       " ('are', 'VBP'),\n",
       " ('some', 'DT'),\n",
       " ('disease', 'NN'),\n",
       " ('features', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('linked', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('adverse', 'JJ'),\n",
       " ('events', 'NNS'),\n",
       " ('AEs', 'NNP'),\n",
       " ('Adults', 'NNP'),\n",
       " ('with', 'IN'),\n",
       " ('ALL', 'NNP'),\n",
       " ('appear', 'VBP'),\n",
       " ('to', 'TO'),\n",
       " ('have', 'VB'),\n",
       " ('even', 'RB'),\n",
       " ('more', 'JJR'),\n",
       " ('neurotoxicity', 'NN'),\n",
       " ('than', 'IN'),\n",
       " ('younger', 'JJR'),\n",
       " ('patients.3', 'NN'),\n",
       " ('I', 'PRP'),\n",
       " ('have', 'VBP'),\n",
       " ('no', 'DT'),\n",
       " ('explanation', 'NN'),\n",
       " ('for', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('Shah', 'NNP'),\n",
       " ('said', 'VBD'),\n",
       " ('If', 'IN'),\n",
       " ('fever', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('hypotension', 'NN'),\n",
       " ('do', 'VBP'),\n",
       " ('not', 'RB'),\n",
       " ('resolve', 'VB'),\n",
       " ('with', 'IN'),\n",
       " ('tocilizumab', 'JJ'),\n",
       " ('my', 'PRP$'),\n",
       " ('own', 'JJ'),\n",
       " ('personal', 'JJ'),\n",
       " ('bias', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('that', 'IN'),\n",
       " ('more', 'JJR'),\n",
       " ('tocilizumab', 'NN'),\n",
       " ('wont', 'NN'),\n",
       " ('help', 'NN'),\n",
       " ('said', 'VBD'),\n",
       " ('Shah', 'NNP'),\n",
       " ('who', 'WP'),\n",
       " ('would', 'MD'),\n",
       " ('resort', 'VB'),\n",
       " ('to', 'TO'),\n",
       " ('steroids', 'VB'),\n",
       " ('in', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('case', 'NN'),\n",
       " ('Theyre', 'NNP'),\n",
       " ('bad', 'JJ'),\n",
       " ('but', 'CC'),\n",
       " ('theyre', 'VBZ'),\n",
       " ('not', 'RB'),\n",
       " ('that', 'IN'),\n",
       " ('bad', 'JJ'),\n",
       " ('He', 'PRP'),\n",
       " ('urged', 'VBD'),\n",
       " ('clinicians', 'NNS'),\n",
       " ('not', 'RB'),\n",
       " ('to', 'TO'),\n",
       " ('be', 'VB'),\n",
       " ('afraid', 'VBN'),\n",
       " ('to', 'TO'),\n",
       " ('put', 'VB'),\n",
       " ('a', 'DT'),\n",
       " ('patient', 'NN'),\n",
       " ('on', 'IN'),\n",
       " ('steroids', 'NNS'),\n",
       " ('as', 'RB'),\n",
       " ('long', 'RB'),\n",
       " ('as', 'IN'),\n",
       " ('they', 'PRP'),\n",
       " ('are', 'VBP'),\n",
       " ('willing', 'JJ'),\n",
       " ('to', 'TO'),\n",
       " ('stop', 'VB'),\n",
       " ('the', 'DT'),\n",
       " ('course', 'NN'),\n",
       " ('once', 'RB'),\n",
       " ('CRS', 'NNP'),\n",
       " ('symptoms', 'NNS'),\n",
       " ('start', 'VBP'),\n",
       " ('to', 'TO'),\n",
       " ('improve', 'VB'),\n",
       " ('Cerebral', 'NNP'),\n",
       " ('edema', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('another', 'DT'),\n",
       " ('challenging', 'VBG'),\n",
       " ('AE', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('the', 'DT'),\n",
       " ('answer', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('nobody', 'JJ'),\n",
       " ('knows', 'NNS'),\n",
       " ('why', 'WRB'),\n",
       " ('cerebral', 'JJ'),\n",
       " ('edema', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('observed', 'VBN'),\n",
       " ('among', 'IN'),\n",
       " ('6', 'CD'),\n",
       " ('patients', 'NNS'),\n",
       " ('treated', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('Junos', 'NNP'),\n",
       " ('trial', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('its', 'PRP$'),\n",
       " ('proposed', 'VBN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('JCAR015', 'NNP'),\n",
       " ('which', 'WDT'),\n",
       " ('resulted', 'VBD'),\n",
       " ('in', 'IN'),\n",
       " ('multiple', 'JJ'),\n",
       " ('deaths', 'NNS'),\n",
       " ('The', 'DT'),\n",
       " ('mechanisms', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('AE', 'NNP'),\n",
       " ('remain', 'VBP'),\n",
       " ('elusive', 'JJ'),\n",
       " ('We', 'PRP'),\n",
       " ('worry', 'VBP'),\n",
       " ('not', 'RB'),\n",
       " ('only', 'RB'),\n",
       " ('about', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('associated', 'JJ'),\n",
       " ('chemotherapy', 'JJ'),\n",
       " ('side', 'NN'),\n",
       " ('effects-nausea', 'NN'),\n",
       " ('vomiting', 'VBG'),\n",
       " ('hair', 'JJ'),\n",
       " ('loss-because', 'NN'),\n",
       " ('they', 'PRP'),\n",
       " ('do', 'VBP'),\n",
       " ('get', 'VB'),\n",
       " ('some', 'DT'),\n",
       " ('low-dose', 'JJ'),\n",
       " ('chemotherapy', 'NN'),\n",
       " ('prior', 'RB'),\n",
       " ('to', 'TO'),\n",
       " ('getting', 'VBG'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T', 'NNP'),\n",
       " ('cells', 'NNS'),\n",
       " ('but', 'CC'),\n",
       " ('the', 'DT'),\n",
       " ('unique', 'JJ'),\n",
       " ('side', 'NN'),\n",
       " ('effects', 'NNS'),\n",
       " ('we', 'PRP'),\n",
       " ('recognize', 'VBP'),\n",
       " ('with', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T', 'NNP'),\n",
       " ('cells', 'NNS'),\n",
       " ('include', 'VBP'),\n",
       " ('CRS', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('neurological', 'JJ'),\n",
       " ('toxicities', 'NNS'),\n",
       " ('The', 'DT'),\n",
       " ('CRS', 'NNP'),\n",
       " ('can', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('in', 'IN'),\n",
       " ('some', 'DT'),\n",
       " ('mild', 'JJ'),\n",
       " ('cases', 'NNS'),\n",
       " ('characterized', 'VBN'),\n",
       " ('by', 'IN'),\n",
       " ('fevers', 'NNS'),\n",
       " ('chills', 'NNS'),\n",
       " ('slightly', 'RB'),\n",
       " ('low', 'JJ'),\n",
       " ('blood', 'NN'),\n",
       " ('pressure', 'NN'),\n",
       " ('that', 'WDT'),\n",
       " ('responds', 'VBZ'),\n",
       " ('to', 'TO'),\n",
       " ('intravenous', 'JJ'),\n",
       " ('fluids', 'NNS'),\n",
       " ('to', 'TO'),\n",
       " ('in', 'IN'),\n",
       " ('extreme', 'JJ'),\n",
       " ('cases', 'NNS'),\n",
       " ('fevers', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('very', 'RB'),\n",
       " ('high', 'JJ'),\n",
       " ('and', 'CC'),\n",
       " ('blood', 'NN'),\n",
       " ('pressure', 'NN'),\n",
       " ('that', 'WDT'),\n",
       " ('drops', 'VBZ'),\n",
       " ('low', 'JJ'),\n",
       " ('enough', 'RB'),\n",
       " ('to', 'TO'),\n",
       " ('require', 'VB'),\n",
       " ('medication', 'NN'),\n",
       " ('In', 'IN'),\n",
       " ('terms', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('neurological', 'JJ'),\n",
       " ('toxicity', 'NN'),\n",
       " ('some', 'DT'),\n",
       " ('patients', 'NNS'),\n",
       " ('do', 'VBP'),\n",
       " (\"n't\", 'RB'),\n",
       " ('have', 'VB'),\n",
       " ('any', 'DT'),\n",
       " ('Others', 'NNS'),\n",
       " ('might', 'MD'),\n",
       " ('have', 'VB'),\n",
       " ('mild', 'JJ'),\n",
       " ('confusion', 'NN'),\n",
       " ('In', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('severe', 'JJ'),\n",
       " ('extreme', 'NN'),\n",
       " ('patients', 'NNS'),\n",
       " ('can', 'MD'),\n",
       " ('become', 'VB'),\n",
       " ('comatose', 'JJ'),\n",
       " ('or', 'CC'),\n",
       " ('have', 'VBP'),\n",
       " ('seizures', 'VBN'),\n",
       " ('as', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('result', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('neurotoxicity', 'NN'),\n",
       " ('Thus', 'NNP'),\n",
       " ('far', 'RB'),\n",
       " ('the', 'DT'),\n",
       " ('companies', 'NNS'),\n",
       " ('have', 'VBP'),\n",
       " ('been', 'VBN'),\n",
       " ('very', 'RB'),\n",
       " ('careful', 'JJ'),\n",
       " ('in', 'IN'),\n",
       " ('terms', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('having', 'VBG'),\n",
       " ('sites', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('have', 'VBP'),\n",
       " ('experience', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('adequate', 'JJ'),\n",
       " ('training', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('treat', 'VB'),\n",
       " ('patients', 'NNS'),\n",
       " ('They', 'PRP'),\n",
       " (\"'re\", 'VBP'),\n",
       " ('limiting', 'VBG'),\n",
       " ('the', 'DT'),\n",
       " ('first', 'JJ'),\n",
       " ('roll-out', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('sites', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('able', 'JJ'),\n",
       " ('to', 'TO'),\n",
       " ('manage', 'VB'),\n",
       " ('these', 'DT'),\n",
       " ('toxicities', 'NNS'),\n",
       " ('because', 'IN'),\n",
       " ('it', 'PRP'),\n",
       " ('is', 'VBZ'),\n",
       " ('a', 'DT'),\n",
       " ('multimodality', 'NN'),\n",
       " ('management', 'NN'),\n",
       " ('Questions', 'NNS'),\n",
       " ('about', 'IN'),\n",
       " ('toxicity', 'NN'),\n",
       " ('centered', 'VBN'),\n",
       " ('on', 'IN'),\n",
       " ('how', 'WRB'),\n",
       " ('optimal', 'JJ'),\n",
       " ('management', 'NN'),\n",
       " ('should', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('delivered', 'VBN'),\n",
       " ('Over', 'IN'),\n",
       " ('60', 'CD'),\n",
       " ('suggested', 'VBD'),\n",
       " ('that', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('should', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('monitored', 'VBN'),\n",
       " ('for', 'IN'),\n",
       " ('1', 'CD'),\n",
       " ('to', 'TO'),\n",
       " ('2', 'CD'),\n",
       " ('weeks', 'NNS'),\n",
       " ('after', 'IN'),\n",
       " ('administration', 'NN'),\n",
       " ('Notably', 'RB'),\n",
       " ('one-third', 'JJ'),\n",
       " ('stated', 'VBN'),\n",
       " ('that', 'IN'),\n",
       " ('toxicity', 'NN'),\n",
       " ('might', 'MD'),\n",
       " ('hinder', 'VB'),\n",
       " ('their', 'PRP$'),\n",
       " ('prescribing', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('Additionally', 'RB'),\n",
       " ('the', 'DT'),\n",
       " ('side-effects', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('immunotherapy', 'NN'),\n",
       " ('can', 'MD'),\n",
       " ('overshadow', 'VB'),\n",
       " ('clinical', 'JJ'),\n",
       " ('benefits', 'NNS'),\n",
       " ('and', 'CC'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('proving', 'VBG'),\n",
       " ('to', 'TO'),\n",
       " ('be', 'VB'),\n",
       " ('particularly', 'RB'),\n",
       " ('challenging', 'VBG'),\n",
       " ('for', 'IN'),\n",
       " ('example', 'NN'),\n",
       " ('95', 'CD'),\n",
       " ('of', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('treated', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('axicabtagene', 'JJ'),\n",
       " ('ciloleucel', 'NN'),\n",
       " ('had', 'VBD'),\n",
       " ('adverse', 'JJ'),\n",
       " ('events', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('grade', 'NN'),\n",
       " ('3', 'CD'),\n",
       " ('or', 'CC'),\n",
       " ('worse', 'JJR'),\n",
       " ('including', 'VBG'),\n",
       " ('haematological', 'JJ'),\n",
       " ('and', 'CC'),\n",
       " ('neurological', 'JJ'),\n",
       " ('toxicities', 'NNS'),\n",
       " ('When', 'WRB'),\n",
       " ('asked', 'VBN'),\n",
       " ('about', 'IN'),\n",
       " ('published', 'VBN'),\n",
       " ('information', 'NN'),\n",
       " ('from', 'IN'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trials', 'NNS'),\n",
       " ('almost', 'RB'),\n",
       " ('half', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('participants', 'NNS'),\n",
       " ('were', 'VBD'),\n",
       " ('not', 'RB'),\n",
       " ('familiar', 'JJ'),\n",
       " ('with', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('efficacy', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('toxicity', 'NN'),\n",
       " ('data', 'NNS'),\n",
       " ('on', 'IN'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('Despite', 'IN'),\n",
       " ('most', 'JJS'),\n",
       " ('respondents', 'NNS'),\n",
       " ('labeling', 'VBG'),\n",
       " ('CAR-T', 'JJ'),\n",
       " ('therapy', 'NN'),\n",
       " ('as', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('potentially', 'RB'),\n",
       " ('game-changing', 'JJ'),\n",
       " ('approach', 'NN'),\n",
       " ('only', 'RB'),\n",
       " ('20', 'CD'),\n",
       " ('had', 'VBD'),\n",
       " ('ever', 'RB'),\n",
       " ('referred', 'VBN'),\n",
       " ('a', 'DT'),\n",
       " ('patient', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('a', 'DT'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trial', 'NN'),\n",
       " ('Our', 'PRP$'),\n",
       " ('study', 'NN'),\n",
       " ('highlights', 'NNS'),\n",
       " ('several', 'JJ'),\n",
       " ('findings', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('critical', 'JJ'),\n",
       " ('to', 'TO'),\n",
       " ('all', 'DT'),\n",
       " ('stakeholders', 'NNS'),\n",
       " ('First', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('foremost', 'JJS'),\n",
       " ('lack', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('familiarity', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('published', 'VBN'),\n",
       " ('data', 'NNS'),\n",
       " ('might', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('predictable', 'JJ'),\n",
       " ('since', 'IN'),\n",
       " ('studies', 'NNS'),\n",
       " ('were', 'VBD'),\n",
       " ('conducted', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('refractory', 'NN'),\n",
       " ('diseases', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('commonly', 'RB'),\n",
       " ('treated', 'VBN'),\n",
       " ('at', 'IN'),\n",
       " ('academic', 'JJ'),\n",
       " ('sites', 'NNS'),\n",
       " ('Overcoming', 'VBG'),\n",
       " ('this', 'DT'),\n",
       " ('educational', 'JJ'),\n",
       " ('barrier', 'NN'),\n",
       " ('can', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('achieved', 'VBN'),\n",
       " ('through', 'IN'),\n",
       " ('data', 'NNS'),\n",
       " ('dissemination', 'NN'),\n",
       " ('webinars', 'VBZ'),\n",
       " ('regional', 'JJ'),\n",
       " ('symposia', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('other', 'JJ'),\n",
       " ('venues', 'NNS'),\n",
       " ('When', 'WRB'),\n",
       " ('queried', 'VBN'),\n",
       " ('on', 'IN'),\n",
       " ('how', 'WRB'),\n",
       " ('their', 'PRP$'),\n",
       " ('prescribing', 'NN'),\n",
       " ('habits', 'NNS'),\n",
       " ('might', 'MD'),\n",
       " ('evolve', 'VB'),\n",
       " ('should', 'MD'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('therapies', 'NNS'),\n",
       " ('become', 'VBP'),\n",
       " ('FDA', 'NNP'),\n",
       " ('approved', 'VBD'),\n",
       " ('for', 'IN'),\n",
       " ('indications', 'NNS'),\n",
       " ('studied', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('ongoing', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('completed', 'VBD'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trials', 'NNS'),\n",
       " ('only', 'RB'),\n",
       " ('22', 'CD'),\n",
       " ('suggested', 'VBD'),\n",
       " ('they', 'PRP'),\n",
       " ('are', 'VBP'),\n",
       " ('unlikely', 'JJ'),\n",
       " ('to', 'TO'),\n",
       " ('prescribe', 'VB'),\n",
       " ('CAR-T', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('Lastly', 'NNP'),\n",
       " ('we', 'PRP'),\n",
       " ('inquired', 'VBD'),\n",
       " ('about', 'IN'),\n",
       " ('barriers', 'NNS'),\n",
       " ('to', 'TO'),\n",
       " ('successful', 'JJ'),\n",
       " ('CAR-T', 'JJ'),\n",
       " ('implementation', 'NN'),\n",
       " ('the', 'DT'),\n",
       " ('logistics', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('administration', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('the', 'DT'),\n",
       " ('most', 'RBS'),\n",
       " ('common', 'JJ'),\n",
       " ('barrier', 'NN'),\n",
       " ('followed', 'VBN'),\n",
       " ('by', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('known', 'VBN'),\n",
       " ('and', 'CC'),\n",
       " ('perceived', 'VBN'),\n",
       " ('toxicities', 'NNS'),\n",
       " ('While', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('majority', 'NN'),\n",
       " ('believed', 'VBD'),\n",
       " ('that', 'DT'),\n",
       " ('medical', 'JJ'),\n",
       " ('oncologists', 'NNS'),\n",
       " ('should', 'MD'),\n",
       " ('oversee', 'VB'),\n",
       " ('the', 'DT'),\n",
       " ('management', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('CAR-T-treated', 'JJ'),\n",
       " ('patients', 'NNS'),\n",
       " ('22', 'CD'),\n",
       " ('believed', 'VBD'),\n",
       " ('that', 'IN'),\n",
       " ('engaging', 'VBG'),\n",
       " ('critical', 'JJ'),\n",
       " ('care', 'NN'),\n",
       " ('physicians', 'NNS'),\n",
       " ('will', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('essential', 'JJ'),\n",
       " ('for', 'IN'),\n",
       " ('optimal', 'JJ'),\n",
       " ('care', 'NN'),\n",
       " ('We', 'PRP'),\n",
       " ('have', 'VBP'),\n",
       " ('reported', 'VBN'),\n",
       " ('on', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('very', 'RB'),\n",
       " ('high', 'JJ'),\n",
       " ('response', 'NN'),\n",
       " ('rates', 'NNS'),\n",
       " ('and', 'CC'),\n",
       " ('durable', 'JJ'),\n",
       " ('remission', 'NN'),\n",
       " ('rates', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('ALL', 'NNP'),\n",
       " ('We', 'PRP'),\n",
       " ('have', 'VBP'),\n",
       " ('treated', 'VBN'),\n",
       " ('more', 'JJR'),\n",
       " ('than', 'IN'),\n",
       " ('300', 'CD'),\n",
       " ('patients', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('tisagenlecleucel', 'NN'),\n",
       " ('in', 'IN'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trials', 'NNS'),\n",
       " ('and', 'CC'),\n",
       " ('a', 'DT'),\n",
       " ('lot', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('that', 'DT'),\n",
       " ('information', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('used', 'VBN'),\n",
       " ('for', 'IN'),\n",
       " ('FDA', 'NNP'),\n",
       " ('approval', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('therapy', 'NN'),\n",
       " ('Dr.', 'NNP'),\n",
       " ('Lonial', 'NNP'),\n",
       " ('In', 'IN'),\n",
       " ('my', 'PRP$'),\n",
       " ('experience', 'NN'),\n",
       " ('treating', 'VBG'),\n",
       " ('patients', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('multiple', 'JJ'),\n",
       " ('myeloma', 'VBP'),\n",
       " ('the', 'DT'),\n",
       " ('benefit', 'NN'),\n",
       " ('from', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('therapy', 'NN'),\n",
       " ('has', 'VBZ'),\n",
       " ('been', 'VBN'),\n",
       " ('quite', 'RB'),\n",
       " ('striking', 'VBG'),\n",
       " ('In', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('small', 'JJ'),\n",
       " ('clinical', 'JJ'),\n",
       " ('study', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('second-generation', 'NN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('construct', 'NN'),\n",
       " ('targeting', 'VBG'),\n",
       " ('the', 'DT'),\n",
       " ('B-cell', 'NNP'),\n",
       " ('maturation', 'NN'),\n",
       " ('antigen', 'NN'),\n",
       " ('BCMA', 'NNP'),\n",
       " ('in', 'IN'),\n",
       " ('multiple', 'JJ'),\n",
       " ('myeloma', 'VBP'),\n",
       " ('the', 'DT'),\n",
       " ('overall', 'JJ'),\n",
       " ('response', 'NN'),\n",
       " ('rates', 'NNS'),\n",
       " ('looked', 'VBD'),\n",
       " ('even', 'RB'),\n",
       " ('better', 'JJR'),\n",
       " ('than', 'IN'),\n",
       " ('what', 'WP'),\n",
       " ('weve', 'VBP'),\n",
       " ('seen', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('CD19', 'NNP'),\n",
       " ('in', 'IN'),\n",
       " ('lymphoma', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('ALL.6', 'NNP'),\n",
       " ('Now', 'RB'),\n",
       " ('these', 'DT'),\n",
       " ('are', 'VBP'),\n",
       " ('very', 'RB'),\n",
       " ('very', 'RB'),\n",
       " ('early', 'JJ'),\n",
       " ('days', 'NNS'),\n",
       " ('but', 'CC'),\n",
       " ('I', 'PRP'),\n",
       " ('think', 'VBP'),\n",
       " ('the', 'DT'),\n",
       " ('responses', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('durability', 'NN'),\n",
       " ('are', 'VBP'),\n",
       " ('going', 'VBG'),\n",
       " ('to', 'TO'),\n",
       " ('be', 'VB'),\n",
       " ('quite', 'RB'),\n",
       " ('impressive', 'JJ'),\n",
       " ('Dr.', 'NNP'),\n",
       " ('Maloney', 'NNP'),\n",
       " ('We', 'PRP'),\n",
       " ('have', 'VBP'),\n",
       " ('also', 'RB'),\n",
       " ('published', 'VBN'),\n",
       " ('extensively', 'RB'),\n",
       " ('on', 'IN'),\n",
       " ('our', 'PRP$'),\n",
       " ('clinical', 'JJ'),\n",
       " ('trials', 'NNS'),\n",
       " ('data', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('chronic', 'JJ'),\n",
       " ('lymphocytic', 'JJ'),\n",
       " ('leukemia', 'NN'),\n",
       " ('CLL', 'NNP'),\n",
       " ('lymphoma', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('ALL', 'DT'),\n",
       " ('and', 'CC'),\n",
       " ('there', 'EX'),\n",
       " ('is', 'VBZ'),\n",
       " ('clearly', 'RB'),\n",
       " ('a', 'DT'),\n",
       " ('high', 'JJ'),\n",
       " ('initial', 'JJ'),\n",
       " ('response', 'NN'),\n",
       " ('rate', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('CAR', 'NNP'),\n",
       " ('T-cell', 'NNP'),\n",
       " ('therapy', 'NN'),\n",
       " ('We', 'PRP'),\n",
       " ('are', 'VBP'),\n",
       " ('seeing', 'VBG'),\n",
       " ('remission', 'NN'),\n",
       " ('rates', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('whom', 'WP'),\n",
       " ('we', 'PRP'),\n",
       " ('did', 'VBD'),\n",
       " ('not', 'RB'),\n",
       " ('see', 'VB'),\n",
       " ('any', 'DT'),\n",
       " ('type', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('remission', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('conventional', 'JJ'),\n",
       " ('therapies', 'NNS'),\n",
       " ('Some', 'DT'),\n",
       " ('patients', 'NNS'),\n",
       " ('relapse', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('we', 'PRP'),\n",
       " ('dont', 'VBP'),\n",
       " ('know', 'JJ'),\n",
       " ('whether', 'IN'),\n",
       " ('patients', 'NNS'),\n",
       " ('are', 'VBP'),\n",
       " ('cured', 'VBN'),\n",
       " ('yet', 'RB'),\n",
       " ('and', 'CC'),\n",
       " ('there', 'EX'),\n",
       " ('can', 'MD'),\n",
       " ('be', 'VB'),\n",
       " ('serious', 'JJ'),\n",
       " ('toxicities', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('therapy', 'NN'),\n",
       " ('Patients', 'NNPS'),\n",
       " ('undergoing', 'JJ'),\n",
       " ...]"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nltk.pos_tag(content_noPunc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
